IL107591A - Anti B cell antibodies their preparation and pharmaceutical compositions comprising them - Google Patents

Anti B cell antibodies their preparation and pharmaceutical compositions comprising them

Info

Publication number: IL107591A
Authority: IL; Israel
Prior art keywords: preparation; pharmaceutical compositions; cell antibodies; antibody; cell
Prior art date: 1992-11-13

Application number

IL10759193A

Other languages

English (en)

Other versions

IL107591A0 (en

Original Assignee

Idec Pharma Corp

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1992-11-13

Filing date

1993-11-12

Publication date

2000-02-17

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=25526490&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=IL107591(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

1993-11-12 Application filed by Idec Pharma Corp filed Critical Idec Pharma Corp

1994-02-27 Publication of IL107591A0 publication Critical patent/IL107591A0/xx

2000-02-17 Publication of IL107591A publication Critical patent/IL107591A/xx

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2887—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against CD20
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
- A61K47/6849—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a receptor, a cell surface antigen or a cell surface determinant
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
- C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10S424/00—Drug, bio-affecting and body treating compositions
- Y10S424/80—Antibody or fragment thereof whose amino acid sequence is disclosed in whole or in part
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10S424/00—Drug, bio-affecting and body treating compositions
- Y10S424/801—Drug, bio-affecting and body treating compositions involving antibody or fragment thereof produced by recombinant dna technology
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10S530/00—Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof
- Y10S530/867—Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof involving immunoglobulin or antibody produced via recombinant dna technology

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Immunology (AREA)
Medicinal Chemistry (AREA)
Organic Chemistry (AREA)
General Health & Medical Sciences (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Pharmacology & Pharmacy (AREA)
Animal Behavior & Ethology (AREA)
Biochemistry (AREA)
Engineering & Computer Science (AREA)
Epidemiology (AREA)
Bioinformatics & Cheminformatics (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Biophysics (AREA)
Genetics & Genomics (AREA)
Molecular Biology (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Cell Biology (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Oncology (AREA)
Hematology (AREA)
Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Peptides Or Proteins (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Micro-Organisms Or Cultivation Processes Thereof (AREA)
Preparation Of Compounds By Using Micro-Organisms (AREA)
Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
Medicines Containing Material From Animals Or Micro-Organisms (AREA)

IL10759193A 1992-11-13 1993-11-12 Anti B cell antibodies their preparation and pharmaceutical compositions comprising them IL107591A (en)

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
US97889192A	1992-11-13	1992-11-13

Publications (2)

Publication Number	Publication Date
IL107591A0 IL107591A0 (en)	1994-02-27
IL107591A true IL107591A (en)	2000-02-17

Family

ID=25526490

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
IL10759193A IL107591A (en)	1992-11-13	1993-11-12	Anti B cell antibodies their preparation and pharmaceutical compositions comprising them

Country Status (24)

Country	Link
US (2)	US5736137A (fr)
EP (1)	EP2000149B1 (fr)
KR (1)	KR100365632B1 (fr)
CN (5)	CN1607006B (fr)
AT (2)	ATE421335T1 (fr)
BR (1)	BR1100622A (fr)
CA (1)	CA2626445A1 (fr)
DE (3)	DE69334285D1 (fr)
DK (2)	DK2000149T3 (fr)
ES (2)	ES2326144T3 (fr)
FR (1)	FR04C0018I2 (fr)
GE (3)	GEP20074162B (fr)
HK (3)	HK1109634A1 (fr)
HU (1)	HU219264B (fr)
IL (1)	IL107591A (fr)
LU (1)	LU91620I2 (fr)
MY (1)	MY111196A (fr)
NL (1)	NL300424I1 (fr)
PL (1)	PL175557B1 (fr)
PT (2)	PT2000149E (fr)
SG (1)	SG45294A1 (fr)
TW (1)	TW376320B (fr)
UA (1)	UA27946C2 (fr)
ZA (1)	ZA938466B (fr)

Families Citing this family (723)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US4816567A (en)	1983-04-08	1989-03-28	Genentech, Inc.	Recombinant immunoglobin preparations
US5736137A (en) *	1992-11-13	1998-04-07	Idec Pharmaceuticals Corporation	Therapeutic application of chimeric and radiolabeled antibodies to human B lymphocyte restricted differentiation antigen for treatment of B cell lymphoma
US7744877B2 (en) *	1992-11-13	2010-06-29	Biogen Idec Inc.	Expression and use of anti-CD20 Antibodies
PT752248E (pt) *	1992-11-13	2001-01-31	Idec Pharma Corp	Aplicacao terapeutica de anticorpos quimericos e marcados radioactivamente contra antigenios de diferenciacao restrita de linfocitos b humanos para o tratamento do linfoma de celulas b
US5595721A (en)	1993-09-16	1997-01-21	Coulter Pharmaceutical, Inc.	Radioimmunotherapy of lymphoma using anti-CD20
US5885574A (en) *	1994-07-26	1999-03-23	Amgen Inc.	Antibodies which activate an erythropoietin receptor
ATE306930T1 (de) *	1994-08-12	2005-11-15	Immunomedics Inc	Für b-zell-lymphom und leukämiezellen spezifische immunkonjugate und humane antikörper
US8771694B2 (en) *	1994-08-12	2014-07-08	Immunomedics, Inc.	Immunoconjugates and humanized antibodies specific for B-cell lymphoma and leukemia cells
US20030180290A1 (en) *	1995-06-07	2003-09-25	Idec Pharmaceuticals Corporation	Anti-CD80 antibody having ADCC activity for ADCC mediated killing of B cell lymphoma cells alone or in combination with other therapies
US6373497B1 (en) *	1999-05-14	2002-04-16	Zight Corporation	Time sequential lookup table arrangement for a display
US6893636B2 (en) *	1997-02-20	2005-05-17	Biogen Idec Ma Inc.	Gamma-1 and gamma-3 anti-human CD23 monoclonal antibodies and use thereof as therapeutics
US7033589B1 (en) *	1997-02-20	2006-04-25	Biogen Idec Ma Inc.	γ-1 anti-human CD23 monoclonal antibodies and use thereof as therapeutics
US6171586B1 (en) *	1997-06-13	2001-01-09	Genentech, Inc.	Antibody formulation
US6991790B1 (en) *	1997-06-13	2006-01-31	Genentech, Inc.	Antibody formulation
US20020088019A1 (en) *	1997-09-02	2002-07-04	Oron Yacoby-Zeevi	Methods of and pharmaceutical compositions for improving implantation of embryos
US20040213789A1 (en) *	1997-09-02	2004-10-28	Oron Yacoby-Zeevi	Heparanase activity neutralizing anti-heparanase monoclonal antibody and other anti-heparanase antibodies
US6699672B1 (en) *	1997-09-02	2004-03-02	Insight Biopharmaceuticals Ltd.	Heparanase specific molecular probes and their use research and medical applications
US20030161823A1 (en) *	1998-08-31	2003-08-28	Neta Ilan	Therapeutic and cosmetic uses of heparanases
US6177545B1 (en) *	1997-09-02	2001-01-23	Insight Strategy & Marketing Ltd.	Heparanase specific molecular probes and their use in research and medical applications
US6562950B2 (en) *	1997-09-02	2003-05-13	Insight Strategy & Marketing Ltd.	Heparanase activity neutralizing anti-heparanase monoclonal antibody
US20010006630A1 (en) *	1997-09-02	2001-07-05	Oron Yacoby-Zeevi	Introducing a biological material into a patient
US6194551B1 (en)	1998-04-02	2001-02-27	Genentech, Inc.	Polypeptide variants
US6528624B1 (en) *	1998-04-02	2003-03-04	Genentech, Inc.	Polypeptide variants
US6242195B1 (en)	1998-04-02	2001-06-05	Genentech, Inc.	Methods for determining binding of an analyte to a receptor
EP2261229A3 (fr) *	1998-04-20	2011-03-23	GlycArt Biotechnology AG	Modification par glycosylation d'anticorps aux fins d'amélioration de la cytotoxicité cellulaire dépendant des anticorps
US6455043B1 (en)	1998-08-11	2002-09-24	Idec Pharmaceuticals Corporation	Combination therapies for B-cell lymphomas comprising administration of anti-CD20 antibody
US20030217375A1 (en) *	1998-08-31	2003-11-20	Eyal Zcharia	Transgenic animals expressing heparanase and uses thereof
US6224866B1 (en)	1998-10-07	2001-05-01	Biocrystal Ltd.	Immunotherapy of B cell involvement in progression of solid, nonlymphoid tumors
US20010033839A1 (en) *	1999-10-04	2001-10-25	Emilio Barbera-Guillem	Vaccine and immunotherapy for solid nonlymphoid tumor and related immune dysregulation
EP2289543A1 (fr)	1998-11-09	2011-03-02	Biogen Idec Inc.	Utilisation d'anticorps chimère anti-CD20 pour le traitement de tumeurs malignes hématologiques associés avec celles tumorales circulantes.
ATE454166T1 (de) *	1998-11-09	2010-01-15	Biogen Idec Inc	Behandlung von patienten die eine knochenmarktransplantation oder eine transplantation peripherer blutstammzellen erhalten mit anti-cd20 antikörpern
WO2000029431A1 (fr) *	1998-11-17	2000-05-25	Tanox, Inc.	Reticulation de molecules bispecifiques du motif d'activation a base de tyrosine des immunorecepteurs avec le motif d'inhibition a base de tyrosine des immunorecepteurs, dans un but therapeutique
US7183387B1 (en)	1999-01-15	2007-02-27	Genentech, Inc.	Polypeptide variants with altered effector function
EP1141024B1 (fr)	1999-01-15	2018-08-08	Genentech, Inc.	POLYPEPTIDE COMPRENANT UNE VARIANTE DE LA REGION Fc DE L'IgG1 HUMAIN
US6737056B1 (en)	1999-01-15	2004-05-18	Genentech, Inc.	Polypeptide variants with altered effector function
MY133346A (en) *	1999-03-01	2007-11-30	Biogen Inc	Kit for radiolabeling ligands with yttrium-90
US20020102208A1 (en)	1999-03-01	2002-08-01	Paul Chinn	Radiolabeling kit and binding assay
AU2878600A (en) *	1999-03-01	2000-09-21	Hadasit Medical Research Services & Development Company Ltd	Polynucleotide encoding a polypeptide having heparanase activity and expression of same in genetically modified cells
SI1176981T1 (sl)	1999-05-07	2006-04-30	Genentech Inc	Zdravljenje avtoimunskih bolezni z antagonisti, ki se vezejo na B celicne povrsinske markerje
JP2002544174A (ja) *	1999-05-07	2002-12-24	ジェネンテック・インコーポレーテッド	Ｂ細胞表面マーカーに結合するアンタゴニストを用いた自己免疫疾患の治療
CA2375912C (fr) *	1999-06-09	2014-03-11	Immunomedics, Inc.	Immunotherapie de troubles auto-immuns a l'aide d'anticorps ciblant les cellules b
ITMI991299A1 (it) *	1999-06-11	2000-12-11	Consiglio Nazionale Ricerche	Uso di anticorpi contro antigeni di superficie per il trattamento della malattia trapianto contro ospite
US6949245B1 (en) *	1999-06-25	2005-09-27	Genentech, Inc.	Humanized anti-ErbB2 antibodies and treatment with anti-ErbB2 antibodies
US7041292B1 (en)	1999-06-25	2006-05-09	Genentech, Inc.	Treating prostate cancer with anti-ErbB2 antibodies
US20030086924A1 (en) *	1999-06-25	2003-05-08	Genentech, Inc.	Treatment with anti-ErbB2 antibodies
US20040013667A1 (en) *	1999-06-25	2004-01-22	Genentech, Inc.	Treatment with anti-ErbB2 antibodies
KR100754049B1 (ko) *	1999-06-25	2007-08-31	제넨테크, 인크.	전립선암을 치료하기 위한 약제 제조에 사용되는 항-ErbB2 항체 및 조성물
CA2379274A1 (fr) *	1999-07-12	2001-01-18	Genentech, Inc.	Blocage d'une reponse immunitaire a un antigene etranger au moyen d'un antagoniste de liaison a cd20
US6451284B1 (en) *	1999-08-11	2002-09-17	Idec Pharmaceuticals Corporation	Clinical parameters for determining hematologic toxicity prior to radioimmunotheraphy
US8557244B1 (en)	1999-08-11	2013-10-15	Biogen Idec Inc.	Treatment of aggressive non-Hodgkins lymphoma with anti-CD20 antibody
WO2001013945A1 (fr) *	1999-08-23	2001-03-01	Biocrystal Ltd.	Methodes et compositions d'immunotherapie destines au traitement des lymphocytes b impliques dans la progression d'un etat pathologique tel que la sclerose en plaques
KR20020072277A (ko) *	1999-11-08	2002-09-14	아이덱 파마슈티칼즈 코포레이션	항-ｃｄ20 항체 및/또는 화학요법 및 방사선요법과결합하여 항-ｃｄ40ｌ 항체를 이용한 ｂ세포 악성종양의치료방법
US20020028178A1 (en) *	2000-07-12	2002-03-07	Nabil Hanna	Treatment of B cell malignancies using combination of B cell depleting antibody and immune modulating antibody related applications
ATE329610T1 (de) *	2000-02-16	2006-07-15	Genentech Inc	Anti-april antikörper und hybridomazellen
US20030185796A1 (en) *	2000-03-24	2003-10-02	Chiron Corporation	Methods of therapy for non-hodgkin's lymphoma
CA2404365A1 (fr) *	2000-03-31	2001-10-11	Idec Pharmaceutical Corporation	Utilisation combinee d'anticorps ou d'antagonistes anti-cytokine et d'anti-cd20 pour le traitement du lymphome b
IL151853A0 (en)	2000-04-11	2003-04-10	Genentech Inc	Multivalent antibodies and uses therefor
EP2264072A1 (fr)	2000-04-13	2010-12-22	The Rockefeller University	Amélioration de la réponse cytotoxique à médiation d'anticorps.
CN1437478A (zh) *	2000-04-25	2003-08-20	Idec药物公司	瑞图希单抗的鞘内施用,用于中枢神经系统淋巴瘤的治疗
AU2001259271A1 (en) *	2000-04-28	2001-11-12	Millennium Pharmaceuticals, Inc.	14094, a novel human trypsin family member and uses thereof
KR20030007640A (ko) *	2000-05-19	2003-01-23	제넨테크, 인크.	ＥｒｂＢ 길항제에 의한 암 치료요법에 대한 효과적인반응의 가능성을 개선시키기 위한 유전자 검출 분석
CA2411102A1 (fr) *	2000-06-20	2001-12-27	Idec Pharmaceutical Corporation	Traitement de maladies associees aux cellules beta telles que les maladies auto-immunes a caractere malin par combinaison anticorps anti-cd20 froid/anticorps anti-cd22 radiomarque
EP1292334A4 (fr) *	2000-06-22	2003-11-19	Idec Pharma Corp	Proteine de fusion bispecifique et son procede d'utilisation permettant d'ameliorer l'action tueuse de cellules effectives sur des cellules cibles
US20060034830A1 (en) *	2000-06-28	2006-02-16	Gerngross Tillman U	Immunoglobulins comprising predominantly a GalGlcNAcMan5GLcNAc2 glycoform
US20060029604A1 (en) *	2000-06-28	2006-02-09	Gerngross Tillman U	Immunoglobulins comprising predominantly a GlcNAc2Man3GlcNAc2 glycoform
US20060034828A1 (en) *	2000-06-28	2006-02-16	Gerngross Tillman U	Immunoglobulins comprising predominantly a GlcNAcMAN5GLCNAC2 glycoform
US20060024304A1 (en) *	2000-06-28	2006-02-02	Gerngross Tillman U	Immunoglobulins comprising predominantly a Man5GlcNAc2 glycoform
CN1446104A (zh) *	2000-07-12	2003-10-01	Idec药物公司	利用b细胞排除抗体和免疫调制抗体联合治疗b细胞恶性肿瘤的相关应用
CA2422076A1 (fr) *	2000-09-18	2002-03-21	Idec Pharmaceutical Corporation	Polytherapie pour le traitement de maladies auto-immunes utilisant une combinaison d'anticorps d'immunoregulation/de depletion de cellules b
AU2002213357A1 (en) *	2000-10-20	2002-05-06	Idec Pharmaceuticals Corporation	Variant igg3 rituxan r and therapeutic use thereof
US7507724B2 (en)	2001-01-16	2009-03-24	Sloan-Kettering Institute For Cancer Research	Therapy-enhancing glucan
US7906492B2 (en) *	2001-01-16	2011-03-15	Sloan-Kettering Institute For Cancer Research	Therapy-enhancing glucan
AU2002241922B2 (en) *	2001-01-17	2007-10-25	Aptevo Research And Development Llc	Binding domain-immunoglobulin fusion proteins
US7829084B2 (en) *	2001-01-17	2010-11-09	Trubion Pharmaceuticals, Inc.	Binding constructs and methods for use thereof
US7754208B2 (en) *	2001-01-17	2010-07-13	Trubion Pharmaceuticals, Inc.	Binding domain-immunoglobulin fusion proteins
US20030133939A1 (en)	2001-01-17	2003-07-17	Genecraft, Inc.	Binding domain-immunoglobulin fusion proteins
AU2008200400B2 (en) *	2001-01-17	2012-06-07	Aptevo Research And Development Llc	Binding domain-immunoglobulin fusion proteins
US20020159996A1 (en)	2001-01-31	2002-10-31	Kandasamy Hariharan	Use of CD23 antagonists for the treatment of neoplastic disorders
US20030211107A1 (en) *	2002-01-31	2003-11-13	Kandasamy Hariharan	Use of CD23 antagonists for the treatment of neoplastic disorders
US20070065436A1 (en) *	2001-01-31	2007-03-22	Biogen Idec Inc.	Anti-cd80 antibody having adcc activity for adcc mediated killing of b cell lymphoma cells alone or in combination with other therapies
US20030103971A1 (en) *	2001-11-09	2003-06-05	Kandasamy Hariharan	Immunoregulatory antibodies and uses thereof
EP2067486A1 (fr)	2001-01-31	2009-06-10	Biogen Idec Inc.	Utilisation d'antagonistes CD23 dans le traitement des troubles neoplasiques
JP4463475B2 (ja)	2001-01-31	2010-05-19	バイオジェンアイデックインコーポレイテッド	腫瘍疾患の治療における免疫調節性抗体の使用
WO2002078766A2 (fr) *	2001-04-02	2002-10-10	Genentech, Inc.	Polytherapie
US20030003097A1 (en) *	2001-04-02	2003-01-02	Idec Pharmaceutical Corporation	Recombinant antibodies coexpressed with GnTIII
EP1383544A4 (fr) *	2001-04-09	2007-12-12	Progenics Pharm Inc	Immunotoxines anti-cd19
US20020193569A1 (en) *	2001-06-04	2002-12-19	Idec Pharmaceuticals Corporation	Bispecific fusion protein and method of use for enhancing effector cell killing of target cells
US20030087372A1 (en) *	2001-06-13	2003-05-08	Genentech, Inc.	Methods of culturing animal cells and polypeptide production in animal cells
KR20100018071A (ko)	2001-08-03	2010-02-16	글리카트 바이오테크놀로지 아게	항체 의존적 세포 독성이 증가된 항체 글리코실화 변이체
BR0211614A (pt) *	2001-08-03	2006-10-31	Genentech Inc	polipeptìdeo tacis e br3 e empregos dos mesmos
WO2003016470A2 (fr) *	2001-08-10	2003-02-27	University Of Virginia Patent Foundation	Amelioration de l'efficacite des immunotherapies par supplementation de complement
DE60234382D1 (de)	2001-09-17	2009-12-24	Life Technologies Corp	Nanokristalle
US7214428B2 (en) *	2001-09-17	2007-05-08	Invitrogen Corporation	Highly luminescent functionalized semiconductor nanocrystals for biological and physical applications
US7205048B2 (en) *	2001-09-17	2007-04-17	Invitrogen Corporation	Functionalized fluorescent nanocrystal compositions and methods of making
AU2002327037A1 (en)	2001-09-20	2003-04-01	Board Of Regents, The University Of Texas System	Measuring circulating therapeutic antibody, antigen and antigen/antibody complexes using elisa assays
CN105131104B (zh)	2001-10-10	2018-11-16	诺和诺德公司	肽的重构和糖缀合
US8323903B2 (en) *	2001-10-12	2012-12-04	Life Technologies Corporation	Antibody complexes and methods for immunolabeling
US20050069962A1 (en)	2001-10-12	2005-03-31	Archer Robert M	Antibody complexes and methods for immunolabeling
ES2311634T3 (es) *	2001-10-19	2009-02-16	Centre Hospitalier Regional Et Universitaire De Tours	Procedimientos y composiciones para evaluar la respuesta a un tratamiento de anticuerpo.
NZ532526A (en) *	2001-10-25	2007-01-26	Genentech Inc	Compositions comprising a glycoprotein having a Fc region
US6671189B2 (en) *	2001-11-09	2003-12-30	Minebea Co., Ltd.	Power converter having primary and secondary side switches
AU2002364956C1 (en)	2001-11-16	2009-05-28	Biogen Idec Inc.	Polycistronic expression of antibodies
US20060024292A1 (en) *	2001-12-27	2006-02-02	Gerngross Tillman U	Immunoglobulins comprising predominantly a Gal2GlcNAc2Man3GlcNAc2 glycoform
CA2473144C (fr)	2002-02-05	2013-05-28	Genentech, Inc.	Purification de proteines
AU2003216436A1 (en)	2002-02-08	2003-09-02	Life Technologies Corporation	Compositions and methods for restoring immune responsiveness in patients with immunological defects
US8287864B2 (en) *	2002-02-14	2012-10-16	Immunomedics, Inc.	Structural variants of antibodies for improved therapeutic characteristics
AU2003208415B2 (en)	2002-02-14	2009-05-28	Immunomedics, Inc.	Anti-CD20 antibodies and fusion proteins thereof and methods of use
US20040002587A1 (en) *	2002-02-20	2004-01-01	Watkins Jeffry D.	Fc region variants
US20160279239A1 (en)	2011-05-02	2016-09-29	Immunomedics, Inc.	Subcutaneous administration of anti-cd74 antibody for systemic lupus erythematosus and autoimmune disease
US8361464B2 (en)	2002-03-01	2013-01-29	Immunomedics, Inc.	Anthracycline-Antibody Conjugates for Cancer Therapy
US20090042291A1 (en) *	2002-03-01	2009-02-12	Xencor, Inc.	Optimized Fc variants
DK1483294T3 (da) *	2002-03-01	2010-11-08	Immunomedics Inc	Internaliserende anti-CD74-antistoffer og fremgangsmåder til deres anvendelse
US20040132101A1 (en)	2002-09-27	2004-07-08	Xencor	Optimized Fc variants and methods for their generation
US8093357B2 (en) *	2002-03-01	2012-01-10	Xencor, Inc.	Optimized Fc variants and methods for their generation
US20030180292A1 (en) *	2002-03-14	2003-09-25	Idec Pharmaceuticals	Treatment of B cell malignancies using anti-CD40L antibodies in combination with anti-CD20 antibodies and/or chemotherapeutics and radiotherapy
ES2545067T3 (es)	2002-04-26	2015-09-08	Genentech, Inc.	Purificación de proteínas basada en la no afinidad
AU2003256836A1 (en) *	2002-07-25	2004-02-16	Genentech, Inc.	Taci antibodies and uses thereof
US8187593B2 (en) *	2002-08-14	2012-05-29	Macrogenics, Inc.	FcγRIIB specific antibodies and methods of use thereof
US8946387B2 (en) *	2002-08-14	2015-02-03	Macrogenics, Inc.	FcγRIIB specific antibodies and methods of use thereof
US8044180B2 (en) *	2002-08-14	2011-10-25	Macrogenics, Inc.	FcγRIIB specific antibodies and methods of use thereof
US8193318B2 (en) *	2002-08-14	2012-06-05	Macrogenics, Inc.	FcγRIIB specific antibodies and methods of use thereof
US8968730B2 (en)	2002-08-14	2015-03-03	Macrogenics Inc.	FcγRIIB specific antibodies and methods of use thereof
JP4580340B2 (ja)	2002-09-27	2010-11-10	ゼンコー・インコーポレイテッド	最適化Ｆｃ変異体およびそれらの生成方法
JP4662473B2 (ja) *	2002-10-17	2011-03-30	ゲンマブエー／エス	Ｃｄ２０に対するヒトモノクローナル抗体
JP4033390B2 (ja) *	2002-10-30	2008-01-16	独立行政法人科学技術振興機構	不死化ナチュラルキラー細胞株
JP2006516117A (ja) *	2002-11-21	2006-06-22	ジェネンテック・インコーポレーテッド	抗ＥｒｂＢ２抗体を用いた非悪性疾病または疾患の治療
SE0203731D0 (sv) *	2002-12-13	2002-12-13	Mitra Medical Technology Ab	Reagent
JP4351674B2 (ja) *	2002-12-16	2009-10-28	ジェネンテック・インコーポレーテッド	免疫グロブリン変異体とその使用法およびその使用
EP1587540B1 (fr) *	2003-01-09	2021-09-15	MacroGenics, Inc.	Identification et elaboration d'anticorps avec des regions du variant fc et procedes d'utilisation associes
US7960512B2 (en)	2003-01-09	2011-06-14	Macrogenics, Inc.	Identification and engineering of antibodies with variant Fc regions and methods of using same
JP4177123B2 (ja) *	2003-01-10	2008-11-05	富士通株式会社	配線図形検証方法、プログラム及び装置
US20040202666A1 (en) *	2003-01-24	2004-10-14	Immunomedics, Inc.	Anti-cancer anthracycline drug-antibody conjugates
EA200501197A1 (ru) *	2003-01-27	2006-04-28	Байоджен Айдек Ма Инк.	Композиции и способы для лечения злокачественной опухоли с применением igsf9 и liv - 1
US8388955B2 (en) *	2003-03-03	2013-03-05	Xencor, Inc.	Fc variants
US20090010920A1 (en) *	2003-03-03	2009-01-08	Xencor, Inc.	Fc Variants Having Decreased Affinity for FcyRIIb
UA91961C2 (ru)	2003-04-09	2010-09-27	Дженентек, Инк.	Лечение аутоимунных заболеваний у пациента с неадекватным ответом на ингибитор tnf-альфа
TWI353991B (en)	2003-05-06	2011-12-11	Syntonix Pharmaceuticals Inc	Immunoglobulin chimeric monomer-dimer hybrids
KR101412271B1 (ko) *	2003-05-09	2014-06-25	듀크 유니버시티	Ｃｄ２０-특이적 항체 및 이를 이용한 방법
WO2005000351A2 (fr) *	2003-06-05	2005-01-06	Genentech, Inc.	Polytherapie contre les dereglements des lymphocytes b
US20050163775A1 (en) *	2003-06-05	2005-07-28	Genentech, Inc.	Combination therapy for B cell disorders
WO2004108065A2 (fr) *	2003-06-09	2004-12-16	Insight Biopharmaceuticals Ltd.	Activite d'heparanase neutralisant un anticorps monoclonal anti-heparanase et d'autres anticorps anti-heparanase
US7754209B2 (en)	2003-07-26	2010-07-13	Trubion Pharmaceuticals	Binding constructs and methods for use thereof
JP4599355B2 (ja)	2003-07-28	2010-12-15	ジェネンテック，インコーポレイテッド	プロテインａアフィニティークロマトグラフィーの間のプロテインａの浸出の低減
RU2370775C2 (ru) *	2003-07-29	2009-10-20	Дженентек, Инк.	Анализ нейтрализующих антител и его применение
CA2535895A1 (fr) *	2003-08-29	2005-03-17	Genentech, Inc.	Traitement de troubles oculaires
US20060134105A1 (en) *	2004-10-21	2006-06-22	Xencor, Inc.	IgG immunoglobulin variants with optimized effector function
US8399618B2 (en)	2004-10-21	2013-03-19	Xencor, Inc.	Immunoglobulin insertions, deletions, and substitutions
US8101720B2 (en) *	2004-10-21	2012-01-24	Xencor, Inc.	Immunoglobulin insertions, deletions and substitutions
US9714282B2 (en)	2003-09-26	2017-07-25	Xencor, Inc.	Optimized Fc variants and methods for their generation
US8883147B2 (en)	2004-10-21	2014-11-11	Xencor, Inc.	Immunoglobulins insertions, deletions, and substitutions
JP4948174B2 (ja)	2003-10-16	2012-06-06	マイクロメットアクツィエンゲゼルシャフト	多重特異的脱免疫ｃｄ３−結合物質
EP1684869B1 (fr)	2003-11-04	2011-07-20	Novartis Vaccines and Diagnostics, Inc.	Procedes de therapie pour des cancers lies a la cellule b
CN1878568A (zh)	2003-11-05	2006-12-13	盘林京有限公司	Cdim结合抗体的增强的b细胞细胞毒性
NZ547589A (en) *	2003-11-05	2009-05-31	Glycart Biotechnology Ag	CD20 antibodies with increased Fc receptor binding affinity and effector function
EP2385069A3 (fr)	2003-11-12	2012-05-30	Biogen Idec MA Inc.	Variantes de polypeptides Fc se liant au récepteur (FcRn) néonatal, protéines Fc dimèriques et procédés correspondants
WO2005060520A2 (fr) *	2003-11-25	2005-07-07	Dana-Farber Cancer Institute, Inc.	Anticorps diriges contre sras-cov et methodes d'utilisation de ceux-ci
WO2005060999A2 (fr) *	2003-12-19	2005-07-07	Genentech, Inc.	Detection cd20 pour traitement des maladies auto-immunes
CN1918181A (zh) *	2003-12-19	2007-02-21	健泰科生物技术公司	移植排斥中cd20的检测
FR2867982B1 (fr) *	2004-03-26	2007-07-20	Jean Marie Andrieu	Procede pour amplifier l'activite de vaccins therapeutiques
US20060002930A1 (en) *	2004-04-16	2006-01-05	Genentech, Inc.	Treatment of disorders
JP2007532681A (ja) *	2004-04-16	2007-11-15	ジェネンテック・インコーポレーテッド	Ｂ細胞の枯渇を増大させる方法
BRPI0509419A (pt) *	2004-04-16	2007-09-04	Genentech Inc	método de ensaio imunossorvente ligado por enzimas, anticorpos, hibridoma e kit de imunoensaio
JP5848861B2 (ja) *	2004-04-20	2016-01-27	ジェンマブエー／エスＧｅｎｍａｂＡ／Ｓ	Ｃｄ２０に対するヒトモノクローナル抗体
ZA200608982B (en) *	2004-05-05	2008-06-25	Genentech Inc	Preventing autoimmune disease by using an anti-CD20 antibody
US20050265966A1 (en)	2004-05-20	2005-12-01	Kindsvogel Wayne R	Methods of treating cancer using IL-21 and monoclonal antibody therapy
CA2568336A1 (fr) *	2004-06-04	2005-12-22	Genentech, Inc.	Methode de traitement du lupus
AU2005249566B2 (en) *	2004-06-04	2010-11-11	Genentech, Inc.	Method for treating multiple sclerosis
US9109255B2 (en) *	2004-06-18	2015-08-18	The Board Of Trustees Of The Leland Stanford Junior University	Methods and compositions for determining responsiveness to antibody therapy
AU2005272993B2 (en)	2004-07-15	2010-02-11	Xencor, Inc.	Optimized Fc variants
BRPI0513100A (pt) *	2004-07-22	2007-10-23	Genentech Inc	métodos de tratamento da sìndrome de sjÍgren e artigos manufaturados
WO2006012500A2 (fr)	2004-07-23	2006-02-02	Genentech, Inc.	Cristallisation d'anticorps ou de fragments de ceux-ci
KR100864549B1 (ko)	2004-08-04	2008-10-20	어플라이드 몰리큘라 에볼류션, 인코포레이티드	변이체 ｆｃ 영역
US20060172133A1 (en) *	2004-08-17	2006-08-03	Imad Naasani	Synthesis of highly luminescent colloidal particles
US20060067930A1 (en) *	2004-08-19	2006-03-30	Genentech, Inc.	Polypeptide variants with altered effector function
KR101247908B1 (ko) *	2004-09-02	2013-03-26	제넨테크, 인크.	항-ｆｃ-감마 ｒｉｉｂ 수용체 항체 및 그의 용도
US7662926B2 (en) *	2004-09-02	2010-02-16	Genentech, Inc.	Anti-Fc-gamma receptor antibodies, bispecific variants and uses therefor
US7655229B2 (en) *	2004-09-02	2010-02-02	Chan Andrew C	Anti-FC-gamma RIIB receptor antibody and uses therefor
US20090317384A1 (en) *	2004-09-08	2009-12-24	Genentech, Inc.	Methods of using death receptor ligands and cd20 antibodies
RU2007112952A (ru) *	2004-09-08	2008-10-20	Дженентек, Инк. (Us)	Способы применения лигандов рецепторов смерти и cd20-антител
CA2580271A1 (fr) *	2004-10-05	2006-04-20	Genentech, Inc.	Methode de traitement de l'angeite
JO3000B1 (ar)	2004-10-20	2016-09-05	Genentech Inc	مركبات أجسام مضادة .
EP1809720B1 (fr) *	2004-10-29	2012-05-02	Life Technologies Corporation	Nanocristaux fluorescents fonctionnalisés et leurs procédés de préparation et d utilisation
AU2005335714B2 (en) *	2004-11-10	2012-07-26	Macrogenics, Inc.	Engineering Fc antibody regions to confer effector function
US8802820B2 (en)	2004-11-12	2014-08-12	Xencor, Inc.	Fc variants with altered binding to FcRn
US8367805B2 (en)	2004-11-12	2013-02-05	Xencor, Inc.	Fc variants with altered binding to FcRn
US20070135620A1 (en) *	2004-11-12	2007-06-14	Xencor, Inc.	Fc variants with altered binding to FcRn
US8546543B2 (en)	2004-11-12	2013-10-01	Xencor, Inc.	Fc variants that extend antibody half-life
BRPI0517837A (pt)	2004-11-12	2008-10-21	Xencor Inc	variantes fc com ligação alterada a fcrn
GB2420976B (en) *	2004-11-19	2006-12-20	Zvi Finkelstein	Therapeutic implant
NZ555286A (en) *	2004-12-17	2010-04-30	Genentech Inc	Antiangiogenesis therapy of autoimmune disease in patients who have failed prior therapy
US7691989B2 (en)	2004-12-22	2010-04-06	Genentech, Inc.	Methods for producing soluble membrane-spanning proteins
EP1674479A1 (fr) *	2004-12-22	2006-06-28	Memorial Sloan-Kettering Cancer Center	Modulation des récepteurs Fc gamma pour optimiser l'immunothérapie
ATE432921T1 (de)	2004-12-23	2009-06-15	Gpc Biotech Ag	Quadratsäurederivate mit antiproliferativer wirkung
MX2007006895A (es) *	2004-12-23	2007-06-26	Hoffmann La Roche	Deteccion de un anticuerpo terapeutico en animal de experimentacion.
WO2006074397A2 (fr)	2005-01-05	2006-07-13	Biogen Idec Ma Inc.	Molecules a liaison cripto
ZA200705459B (en) *	2005-01-13	2008-09-25	Genentech Inc	Treatment method
DOP2006000029A (es) *	2005-02-07	2006-08-15	Genentech Inc	Antibody variants and uses thereof. (variantes de un anticuerpo y usos de las mismas)
TW200714289A (en) *	2005-02-28	2007-04-16	Genentech Inc	Treatment of bone disorders
US20160355591A1 (en)	2011-05-02	2016-12-08	Immunomedics, Inc.	Subcutaneous anti-hla-dr monoclonal antibody for treatment of hematologic malignancies
US8349332B2 (en)	2005-04-06	2013-01-08	Ibc Pharmaceuticals, Inc.	Multiple signaling pathways induced by hexavalent, monospecific and bispecific antibodies for enhanced toxicity to B-cell lymphomas and other diseases
US8475794B2 (en)	2005-04-06	2013-07-02	Ibc Pharmaceuticals, Inc.	Combination therapy with anti-CD74 antibodies provides enhanced toxicity to malignancies, Autoimmune disease and other diseases
US9963510B2 (en)	2005-04-15	2018-05-08	Macrogenics, Inc.	Covalent diabodies and uses thereof
AR053579A1 (es) *	2005-04-15	2007-05-09	Genentech Inc	Tratamiento de la enfermedad inflamatoria intestinal (eii)
US9284375B2 (en) *	2005-04-15	2016-03-15	Macrogenics, Inc.	Covalent diabodies and uses thereof
US11254748B2 (en)	2005-04-15	2022-02-22	Macrogenics, Inc.	Covalent diabodies and uses thereof
EP3479844B1 (fr)	2005-04-15	2023-11-22	MacroGenics, Inc.	Dianticorps covalents et leurs utilisations
WO2006116369A2 (fr) *	2005-04-22	2006-11-02	Genentech, Inc.	Méthode pour traiter la démence ou la maladie d'alzheimer
US8034902B2 (en) *	2005-05-04	2011-10-11	Quark Pharmaceuticals, Inc.	Recombinant antibodies against CD55 and CD59 and uses thereof
CN101228189A (zh) *	2005-05-09	2008-07-23	格黎卡特生物技术股份公司	具有修饰的fc区域和改变的与fc受体的结合的抗原结合分子
ZA200709956B (en) *	2005-05-20	2009-02-25	Genentech Inc	Pretreatment of a biological sample from an autoimmune disease subject
US20090285795A1 (en) *	2005-05-24	2009-11-19	Villoo Morawala Patell	Method for the Production of a Monoclonal Antibody to CD20 for the Treatment of B-Cell Lymphoma
CA2614421A1 (fr)	2005-07-08	2007-01-18	Biogen Idec Ma Inc.	Anticorps anti-sp35 et leurs utilisations
EP1912675B1 (fr)	2005-07-25	2014-02-12	Emergent Product Development Seattle, LLC	Reduction de lymphocytes b au moyen de molecules de liaison specifique de cd37 et specifique de cd20
AU2006272597A1 (en)	2005-07-25	2007-02-01	Emergent Product Development Seattle Llc	Single dose use of CD20-specific binding molecules
US20080279850A1 (en) *	2005-07-25	2008-11-13	Trubion Pharmaceuticals, Inc.	B-Cell Reduction Using CD37-Specific and CD20-Specific Binding Molecules
ES2579602T3 (es)	2005-08-10	2016-08-12	Macrogenics, Inc.	Identificación y modificación de anticuerpos con regiones Fc variantes y métodos de uso de estos
US7612181B2 (en)	2005-08-19	2009-11-03	Abbott Laboratories	Dual variable domain immunoglobulin and uses thereof
US20090215992A1 (en) *	2005-08-19	2009-08-27	Chengbin Wu	Dual variable domain immunoglobulin and uses thereof
EP2500357A3 (fr)	2005-08-19	2012-10-24	Abbott Laboratories	Immunoglobuline à double domaine variable et ses utilisations
EP2520588A1 (fr)	2005-08-19	2012-11-07	Abbott Laboratories	Immunoglobuline à double domaine variable et ses utilisations
AU2006287173A1 (en) *	2005-09-02	2007-03-08	Glycofi, Inc	Immunoglobulins comprising predominantly a GICNAcMan3GIcNAc2 glycoform
WO2007041635A2 (fr)	2005-10-03	2007-04-12	Xencor, Inc.	Variants de fc dotés de propriétés de liaison aux récepteurs fc optimisées
WO2007056411A2 (fr) *	2005-11-08	2007-05-18	Genentech, Inc.	Procede de production d'anticorps pan-specifiques
MY149159A (en)	2005-11-15	2013-07-31	Hoffmann La Roche	Method for treating joint damage
ES2618543T3 (es) *	2005-11-23	2017-06-21	Genentech, Inc.	Métodos y composiciones relacionados con ensayos de linfocitos B
WO2007064911A1 (fr) *	2005-12-02	2007-06-07	Biogen Idec Inc.	Anticorps anti-souris cd20 et leurs utilisations
US8323644B2 (en) *	2006-01-17	2012-12-04	Sloan-Kettering Institute For Cancer Research	Therapy-enhancing glucan
JPWO2007102200A1 (ja) *	2006-03-07	2009-07-23	国立大学法人大阪大学	抗ｃｄ２０モノクローナル抗体
CA2644903A1 (fr) *	2006-03-10	2007-09-20	Macrogenics, Inc.	Identification et modification genetique d'anticorps avec des chaines lourdes de variants et leurs procedes d'utilisation
RU2008141912A (ru)	2006-03-23	2010-04-27	Новартис АГ (CH)	Противоопухолевые лекарства на основе антител к клеточным антигенам
EP3026123A1 (fr)	2006-04-27	2016-06-01	Klaritos, Inc.	Procédé et trousses pour predire la thérapie par anticorps
US20080118978A1 (en)	2006-04-28	2008-05-22	Takashi Sato	Anti-tumor agent
US7727525B2 (en) *	2006-05-11	2010-06-01	City Of Hope	Engineered anti-CD20 antibody fragments for in vivo targeting and therapeutics
ES2489646T3 (es) *	2006-05-26	2014-09-02	Macrogenics, Inc.	Anticuerpos humanizados específicos a Fc gamma RIIB y sus métodos de uso
MX2008015524A (es) *	2006-06-12	2009-01-13	Trubion Pharmaceuticals Inc	Proteinas de union multivalentes monocatenarias con funcion efectora.
EP2505209A1 (fr)	2006-06-26	2012-10-03	MacroGenics, Inc.	Anticorps spécifiques au FcgammaRIIB et procédés d'utilisation associés
WO2008002933A2 (fr)	2006-06-26	2008-01-03	Macrogenics, Inc.	COMBINAISON D'ANTICORPS DE FCγRIIB ET D'ANTICORPS SPÉCIFIQUES DE CD20 ET LEURS PROCÉDÉS D'UTILISATION
FR2902799B1 (fr)	2006-06-27	2012-10-26	Millipore Corp	Procede et unite de preparation d'un echantillon pour l'analyse microbiologique d'un liquide
US8372399B2 (en) *	2006-08-31	2013-02-12	Cardiac Pacemakers, Inc.	Bispecific antibodies and agents to enhance stem cell homing
US20080058922A1 (en) *	2006-08-31	2008-03-06	Cardiac Pacemakers, Inc.	Methods and devices employing vap-1 inhibitors
US8636995B2 (en) *	2006-08-31	2014-01-28	Cardiac Pacemakers, Inc.	Methods and devices to regulate stem cell homing
US20080112961A1 (en) *	2006-10-09	2008-05-15	Macrogenics, Inc.	Identification and Engineering of Antibodies with Variant Fc Regions and Methods of Using Same
US9382327B2 (en)	2006-10-10	2016-07-05	Vaccinex, Inc.	Anti-CD20 antibodies and methods of use
US8652466B2 (en) *	2006-12-08	2014-02-18	Macrogenics, Inc.	Methods for the treatment of disease using immunoglobulins having Fc regions with altered affinities for FcγRactivating and FcγRinhibiting
US8569464B2 (en) *	2006-12-21	2013-10-29	Emd Millipore Corporation	Purification of proteins
WO2008079280A1 (fr) *	2006-12-21	2008-07-03	Millipore Corporation	Purification de protéines
US8362217B2 (en)	2006-12-21	2013-01-29	Emd Millipore Corporation	Purification of proteins
ES2641897T3 (es)	2007-01-05	2017-11-14	University Of Zurich	Procedimiento para proporcionar moléculas de unión y diana específicas de una enfermedad
DE102007001370A1 (de)	2007-01-09	2008-07-10	Curevac Gmbh	RNA-kodierte Antikörper
CN103360495B (zh)	2007-01-09	2016-06-08	比奥根Ma公司	Sp35抗体及其用途
EP2120915B1 (fr)	2007-01-22	2011-09-28	Genentech, Inc.	Précipitation de polyélectrolyte et purification de protéines
US8450348B2 (en) *	2007-02-21	2013-05-28	Forma Tm, Llc	Derivatives of squaric acid with anti-proliferative activity
NZ579594A (en)	2007-03-12	2012-03-30	Esbatech Alcon Biomed Res Unit	Sequence based engineering and optimization of single chain antibodies
US7960139B2 (en)	2007-03-23	2011-06-14	Academia Sinica	Alkynyl sugar analogs for the labeling and visualization of glycoconjugates in cells
WO2008122039A2 (fr) *	2007-04-02	2008-10-09	The Government Of The United States Of America, As Represented By The Secretary, Department Of Health And Human Services	Molécules d'anticorps hybrides médiées par la sélénocystéine
FR2915398B1 (fr) *	2007-04-25	2012-12-28	Lab Francais Du Fractionnement	"ensemble de moyens pour le traitement d'une pathologie maligne, d'une maladie auto-immune ou d'une maladie infectieuse"
EP1995309A1 (fr) *	2007-05-21	2008-11-26	Vivalis	Production de protéine recombinante dans des cellules aviaires EBx
EP2019101A1 (fr) *	2007-07-26	2009-01-28	GPC Biotech AG	Pyrazol[3,4-d]pyrimidin-4-one utile en tant que Inhibiteur de kinase
CN101688200B (zh) *	2007-06-25	2012-08-08	艾斯巴技术,爱尔康生物医药研究装置有限责任公司	单链抗体的基于序列的改造和优化
NZ601946A (en)	2007-06-25	2013-12-20	Esbatech Alcon Biomed Res Unit	Methods of modifying antibodies, and modified antibodies with improved functional properties
US20090324596A1 (en)	2008-06-30	2009-12-31	The Trustees Of Princeton University	Methods of identifying and treating poor-prognosis cancers
US10745701B2 (en)	2007-06-28	2020-08-18	The Trustees Of Princeton University	Methods of identifying and treating poor-prognosis cancers
ES2659829T3 (es)	2007-07-09	2018-03-19	Genentech, Inc.	Prevención de la reducción de enlaces disulfuro durante la producción recombinante de polipéptidos
JP5588865B2 (ja) *	2007-07-31	2014-09-10	リジェネロン・ファーマシューティカルズ・インコーポレイテッド	ヒトｃｄ２０に対するヒト抗体及びその使用方法
EP2197918B1 (fr) *	2007-09-05	2013-12-18	F. Hoffmann-La Roche AG	Polythérapie avec des anticorps anti-cd20 de type i et de type ii
KR101666228B1 (ko)	2007-09-28	2016-10-13	인트렉손 코포레이션	생물치료학적 분자를 발현시키기 위한 치료학적 유전자-스위치 작제물 및 생물반응기, 및 이의 용도
US20090098118A1 (en)	2007-10-15	2009-04-16	Thomas Friess	Combination therapy of a type ii anti-cd20 antibody with an anti-bcl-2 active agent
DK2233149T3 (en)	2007-10-16	2016-05-17	Zymogenetics Inc	COMBINATION OF TRANSMEMBRANAKTIVATOR AND CALCIUM MODULATOR AND cyclophilin-LIGAND INTERAKTOR (TACI) AND ANTI-CD20 MEANS FOR TREATMENT OF AUTO-IMMUNE DISEASE
AU2008316276A1 (en) *	2007-10-22	2009-04-30	Oncolytics Biotech Inc.	Treatment regime for proliferative disorders
US20090110688A1 (en) *	2007-10-24	2009-04-30	Georg Fertig	Combination therapy of type ii anti-cd20 antibody with a proteasome inhibitor
RU2498991C2 (ru)	2007-10-30	2013-11-20	Дженентек, Инк.	Очистка антител с помощью катионообменной хроматографии
WO2009117030A2 (fr) *	2007-12-19	2009-09-24	Macrogenics, Inc.	Compositions améliorées pour la prévention et le traitement de la variole
CA2707791A1 (fr) *	2007-12-21	2009-07-09	Genentech, Inc.	Therapie de patients atteints d'arthrite rhumatoide refractaires au rituximab
HUE044466T2 (hu)	2007-12-26	2019-10-28	Xencor Inc	Megváltozott FcRn-kötõdési képességû Fc variánsok
EP2077281A1 (fr)	2008-01-02	2009-07-08	Bergen Teknologioverforing AS	Anticorps anti-CD20 ou fragments correspondants pour le traitement de syndrome de fatigue chronique
US7914785B2 (en)	2008-01-02	2011-03-29	Bergen Teknologieverforing As	B-cell depleting agents, like anti-CD20 antibodies or fragments thereof for the treatment of chronic fatigue syndrome
ATE548052T1 (de)	2008-01-17	2012-03-15	Philogen Spa	Kombination aus einem anti-edb-fibronectin- antikörper-il-2-fusionsprotein und einem b-zellen bindenden molekül, b-zellen-vorläufern und/oder deren krebserregendem gegenspieler
WO2009092011A1 (fr)	2008-01-18	2009-07-23	Medimmune, Llc	Anticorps obtenus par la cystéine pour conjugaison spécifique d'un site
WO2009097095A2 (fr) *	2008-01-28	2009-08-06	The Regents Of The University Of California	Procédés de traitement des tumeurs malignes
CA2716884C (fr) *	2008-03-25	2017-10-03	Charles Dumontet	Utilisation d'un anticorps anti-cd20 de type ii a cytotoxicite cellulaire accrue dependant des anticorps (adcc) combine au cyclophosphamide, a la vincristine et a la doxorubicine pour traiter les lymphomes non hodgk iniens
MX2010010737A (es) *	2008-04-02	2010-12-20	Macrogenics Inc	Anticuerpos especificos para her2/neu y metodos para utilizar los mismos.
US8669349B2 (en)	2008-04-02	2014-03-11	Macrogenics, Inc.	BCR-complex-specific antibodies and methods of using same
PT2132228E (pt) *	2008-04-11	2011-10-11	Emergent Product Dev Seattle	Imunoterapia de cd37 e sua combinação com um quimioterápico bifuncional
EP2112150B1 (fr)	2008-04-22	2013-10-16	Forma Therapeutics, Inc.	Inhibiteurs Raf améliorés
EP2112152A1 (fr)	2008-04-22	2009-10-28	GPC Biotech AG	Dihydropteridinones comme inhibiteurs Plk
US20100260668A1 (en) *	2008-04-29	2010-10-14	Abbott Laboratories	Dual Variable Domain Immunoglobulins and Uses Thereof
US20090269339A1 (en) *	2008-04-29	2009-10-29	Genentech, Inc.	Responses to immunizations in rheumatoid arthritis patients treated with a cd20 antibody
JP5646457B2 (ja)	2008-04-29	2014-12-24	アッヴィ・インコーポレイテッド	二重可変ドメイン免疫グロブリン及びその使用
US9109026B2 (en) *	2008-06-03	2015-08-18	Abbvie, Inc.	Dual variable domain immunoglobulins and uses thereof
CN102112495A (zh) *	2008-06-03	2011-06-29	雅培制药有限公司	双重可变结构域免疫球蛋白及其用途
WO2010033279A2 (fr) *	2008-06-04	2010-03-25	Macrogenics, Inc.	<sb>anticorps à liaison alteree à fcrn et leurs procedes d'utilisation</sb>
US8999702B2 (en) *	2008-06-11	2015-04-07	Emd Millipore Corporation	Stirred tank bioreactor
PL3241843T3 (pl)	2008-06-25	2021-12-27	Novartis Ag	Optymalizacja rozpuszczalności cząsteczek immunowiążących
EP3266453A1 (fr)	2008-07-03	2018-01-10	Mayo Foundation for Medical Education and Research	Traitement du cancer
KR101054362B1 (ko)	2008-07-03	2011-08-05	재단법인 목암생명공학연구소	재조합 단백질의 푸코스 함량을 감소시키는 방법
JP5674654B2 (ja) *	2008-07-08	2015-02-25	アッヴィ・インコーポレイテッド	プロスタグランジンｅ２二重可変ドメイン免疫グロブリンおよびその使用
CA2729961C (fr)	2008-07-09	2018-05-01	Biogen Idec Ma Inc.	Anticorps anti-lingo, li113, li62 variant co2
KR101030978B1 (ko) *	2008-07-10	2011-04-28	(주) 에이프로젠	동물세포용 재조합 발현벡터
JP5986745B2 (ja)	2008-07-15	2016-09-06	アカデミアシニカＡｃａｄｅｍｉａＳｉｎｉｃａ	Ｐｔｆｅ様のアルミニウム・コート・ガラススライド上のグリカンアレイおよび関連する方法
WO2010009129A2 (fr) *	2008-07-15	2010-01-21	Genentech, Inc.	Méthodes de traitement de maladies auto-immunes utilisant des anticorps cd4
CA2731255C (fr) *	2008-07-21	2018-06-05	David M. Goldenberg	Variants structuraux d'anticorps pour obtenir de meilleures caracteristiques therapeutiques
US8900851B2 (en) *	2008-07-22	2014-12-02	The Research Foundation For The State University Of New York	Multi-well platform
ES2749190T3 (es)	2008-08-14	2020-03-19	Genentech Inc	Métodos para eliminar un contaminante usando cromatografía de membrana de intercambio iónico de desplazamiento de proteínas indígenas
EP2334323A2 (fr)	2008-09-10	2011-06-22	F. Hoffmann-La Roche AG	Compositions et procédés permettant d éviter la dégradation oxydative des protéines
TW201014605A (en)	2008-09-16	2010-04-16	Genentech Inc	Methods for treating progressive multiple sclerosis
CN102257141A (zh) *	2008-10-28	2011-11-23	阿维斯塔根有限公司	表达载体和其加工方法
KR20110097913A (ko) *	2008-12-04	2011-08-31	아보트 러보러터리즈	이원 가변 도메인 면역글로불린 및 이의 용도
GB2466025A (en)	2008-12-08	2010-06-09	Univ Francois Rabelais De Tour	C3/ITGAM polymorphisms and cancer prognosis
US8775090B2 (en)	2008-12-12	2014-07-08	Medimmune, Llc	Crystals and structure of a human IgG Fc variant with enhanced FcRn binding
SG171764A1 (en)	2008-12-16	2011-07-28	Millipore Corp	Purification of proteins
EP2370561B1 (fr)	2008-12-16	2019-08-07	EMD Millipore Corporation	Réacteur à cuve agitée et procédé
KR101781228B1 (ko)	2008-12-19	2017-09-22	바이오겐 인터내셔널 뉴로사이언스 게엠베하	인간 항-알파-시누클레인 자가항체
CA2747326C (fr)	2008-12-22	2017-05-16	Millennium Pharmaceuticals, Inc.	Inhibiteurs d'aurora kinases associes avec des anticorps anti-cd20
WO2010075249A2 (fr)	2008-12-22	2010-07-01	Genentech, Inc.	Méthode de traitement de la polyarthrite rhumatoïde avec des antagonistes de cellules b
AU2009334498A1 (en)	2008-12-31	2011-07-21	Biogen Idec Ma Inc.	Anti-lymphotoxin antibodies
US20110142836A1 (en) *	2009-01-02	2011-06-16	Olav Mella	B-cell depleting agents for the treatment of chronic fatigue syndrome
EP2373339B1 (fr)	2009-01-06	2017-04-19	INSERM (Institut National de la Santé et de la Recherche Médicale)	Agent de déplétion de lymphocytes B pour le traitement de l'athérosclérose
US8435488B2 (en)	2009-02-27	2013-05-07	Genentech, Inc.	Methods and compositions for protein labelling
AR075798A1 (es)	2009-03-05	2011-04-27	Abbott Lab	Proteinas de union a il-17 (interleuquina 17)
US9034324B2 (en)	2009-03-10	2015-05-19	Biogen Idec Ma Inc.	Anti-BCMA antibodies
CN102369011A (zh)	2009-03-12	2012-03-07	健泰科生物技术公司	用于治疗造血恶性肿瘤的磷酸肌醇3-激酶抑制剂化合物与化学治疗剂的组合
EP2233500A1 (fr)	2009-03-20	2010-09-29	LFB Biotechnologies	Variantes Fc optimisées
EP2411412B1 (fr)	2009-03-24	2015-05-27	Teva Biopharmaceuticals USA, Inc.	Anticorps humanisés dirigés contre le polypeptide light et leurs utilisations
AR075982A1 (es)	2009-03-31	2011-05-11	Roche Glycart Ag	Terapia de combinacion de un anticuerpo afucosilado y una o mas de las citoquinas seleccionadas de gm- csf humano, m -csf humano y/o il-3 humano y composicion
WO2010138184A2 (fr)	2009-05-27	2010-12-02	Synageva Biopharma Corp.	Anticorps d'origine aviaire
WO2010145846A1 (fr)	2009-06-15	2010-12-23	Bayer Bioscience N.V.	Plants de nicotinia benthamiana à activité xylosyltransférase déficiente
JP5918129B2 (ja)	2009-06-22	2016-05-18	メディミューン，エルエルシー	部位特異的共役のための操作されたＦｃ領域
WO2011000543A1 (fr) *	2009-06-30	2011-01-06	Philochem Ag	Banque de présentation danticorps murin
UY32808A (es) *	2009-07-29	2011-02-28	Abbott Lab	Inmunoglobulinas como dominio variable dual y usos de las mismas
KR20180105258A (ko)	2009-08-11	2018-09-27	제넨테크, 인크.	글루타민-비함유 세포 배양 배지에서의 단백질의 생성
JP2013501741A (ja)	2009-08-14	2013-01-17	ロシュグリクアートアーゲー	アフコシル化ｃｄ２０抗体とフルダラビン及び／又はミトキサントロンの併用療法
TWI409079B (zh)	2009-08-14	2013-09-21	Roche Glycart Ag	非典型岩藻醣化ｃｄ２０抗體與苯達莫斯汀（ｂｅｎｄａｍｕｓｔｉｎｅ）之組合療法
RU2012112550A (ru)	2009-09-01	2013-10-10	Эбботт Лэборетриз	Иммуноглобулины с двумя вариабельными доменами и их применение
RU2571929C2 (ru)	2009-09-01	2015-12-27	Дженентек, Инк.	Улучшенная очистка белка посредством модифицированного элюирования белка а
WO2011028952A1 (fr)	2009-09-02	2011-03-10	Xencor, Inc.	Compositions et procédés pour une co-liaison bivalente et monovalente simultanée d'antigènes
CN107385034B (zh) *	2009-09-03	2021-08-17	弗·哈夫曼-拉罗切有限公司	用于治疗、诊断和监控类风湿性关节炎的方法
AR078161A1 (es)	2009-09-11	2011-10-19	Hoffmann La Roche	Formulaciones farmaceuticas muy concentradas de un anticuerpo anti cd20. uso de la formulacion. metodo de tratamiento.
HUE036549T2 (hu)	2009-10-07	2018-07-30	Macrogenics Inc	A fukozilezés mértékének megváltozása miatt javított effektor funkciót mutató, Fc-régiót tartalmazó polipeptidek, valamint eljárások alkalmazásukra
MX2012004415A (es)	2009-10-15	2012-05-08	Abbott Lab	Inmunoglobulinas de dominio variable doble y usos de las mismas.
SG2014014823A (en) *	2009-10-19	2014-07-30	Hoffmann La Roche	Non-cross-reactive anti igg antibodies
EP2325185A1 (fr)	2009-10-28	2011-05-25	GPC Biotech AG	Inhibiteur de Plk
UY32979A (es) *	2009-10-28	2011-02-28	Abbott Lab	Inmunoglobulinas con dominio variable dual y usos de las mismas
US10087236B2 (en)	2009-12-02	2018-10-02	Academia Sinica	Methods for modifying human antibodies by glycan engineering
US11377485B2 (en)	2009-12-02	2022-07-05	Academia Sinica	Methods for modifying human antibodies by glycan engineering
WO2011095596A1 (fr)	2010-02-04	2011-08-11	Vivalis	Procédé à alimentation discontinue utilisant un milieu de culture de cellules concentré pour la production efficace de produits biologiques dans des cellules eb66
WO2011097527A2 (fr)	2010-02-04	2011-08-11	Xencor, Inc.	Immunoprotection de fractions thérapeutiques avec des régions fc améliorées
US20110189178A1 (en) *	2010-02-04	2011-08-04	Xencor, Inc.	Immunoprotection of Therapeutic Moieties Using Enhanced Fc Regions
WO2011100403A1 (fr) *	2010-02-10	2011-08-18	Immunogen, Inc	Anticorps anti-cd20 et utilisations de ceux-ci
AR080155A1 (es) *	2010-02-10	2012-03-14	Immunogen Inc	Anticuerpos anti-cd20 y su utilizacion
CN102782131B (zh)	2010-03-02	2015-08-05	协和发酵麒麟株式会社	修饰抗体组合物
PH12012501751A1 (en)	2010-03-04	2012-11-12	Macrogenics Inc	Antibodies reactive with b7-h3, immunologically active fragments thereof and uses thereof
GEP20166442B (en)	2010-03-04	2016-03-10	Macrogenics Inc	Antibodies reactive with b7-h3, immunologically active fragments thereof and uses thereof
CN103124564B (zh)	2010-03-22	2016-11-09	弗·哈夫曼-拉罗切有限公司	对于稳定含有蛋白质的制剂有用的组合物和方法
HUE032519T2 (en)	2010-03-26	2017-09-28	Memorial Sloan Kettering Cancer Center	Antibodies to MUC16 and a procedure for its use
WO2011118739A1 (fr)	2010-03-26	2011-09-29	協和発酵キリン株式会社	Nouvel anticorps ayant un site de modification introduit dans celui-ci, et fragment d'anticorps
EP3208281A1 (fr)	2010-03-29	2017-08-23	Zymeworks, Inc.	Anticorps ayant une fonction effectrice améliorée ou supprimée
EP4450523A2 (fr)	2010-04-02	2024-10-23	Amunix Pharmaceuticals, Inc.	Protéines de fusion de liaison, conjugués protéine de fusion-médicament de liaison, conjugués xten-médicament et leurs procédés de fabrication et d'utilisation
WO2011130332A1 (fr)	2010-04-12	2011-10-20	Academia Sinica	Puces au glycane pour la recherche par criblage haut débit de virus
JP6042801B2 (ja)	2010-04-27	2016-12-14	ロシュグリクアートアーゲー	ｍＴＯＲインヒビターとのアフコシル化ＣＤ２０抗体の併用療法
JP2013525484A (ja)	2010-05-03	2013-06-20	ジェネンテック，インコーポレイテッド	タンパク質含有製剤の粘度を低減させるために有用な組成物及び方法
EP2975409B1 (fr)	2010-05-10	2018-10-31	Academia Sinica	Congénères d'oseltamivir ayant une activité anti-grippale et de détermination de la susceptibilité d'oseltamivir des virus de la grippe
KR101539683B1 (ko)	2010-05-14	2015-07-30	애브비 인코포레이티드	Ｉｌ－１ 결합 단백질
WO2011146394A1 (fr)	2010-05-17	2011-11-24	Millipore Corporation	Polymères répondant à des stimuli pour la purification de biomolécules
SG185737A1 (en)	2010-05-25	2013-01-30	Genentech Inc	Methods of purifying polypeptides
DK2576580T3 (en)	2010-05-28	2016-10-17	Hoffmann La Roche	LOWERING THE lactate AND INCREASE polypeptide production by downregulation of the expression of lactate dehydrogenase, and PYRUVATDEHYDROGENASEKINASE
CA2802756C (fr)	2010-06-24	2021-05-04	Genentech, Inc.	Compositions et methodes pour stabiliser des preparations contenant des proteines
US20120009196A1 (en)	2010-07-08	2012-01-12	Abbott Laboratories	Monoclonal antibodies against hepatitis c virus core protein
NZ605400A (en)	2010-07-09	2015-05-29	Biogen Idec Hemophilia Inc	Chimeric clotting factors
UY33492A (es)	2010-07-09	2012-01-31	Abbott Lab	Inmunoglobulinas con dominio variable dual y usos de las mismas
EP2409993A1 (fr)	2010-07-19	2012-01-25	International-Drug-Development-Biotech	Anticorps Anti-CD19 doté d'une fonction ADCC et d'un profil de glycosylation amélioré
EP2409712A1 (fr)	2010-07-19	2012-01-25	International-Drug-Development-Biotech	Anticorps Anti-CD19 doté de fonctions ADCC et CDC et d'un profil de glycosylation amélioré
EP3029066B1 (fr)	2010-07-29	2019-02-20	Xencor, Inc.	Anticorps à points isoélectriques modifiés
WO2012017925A1 (fr)	2010-08-02	2012-02-09	協和発酵キリン株式会社	Procédé de production d'une substance
CN103154025B (zh)	2010-08-02	2015-07-01	宏观基因有限公司	共价双抗体及其用途
EP2600895A1 (fr)	2010-08-03	2013-06-12	Hoffmann-La Roche AG	Biomarqueurs de la leucémie lymphoïde chronique (llc)
AR082461A1 (es)	2010-08-03	2012-12-12	Abbott Lab	Inmunoglobulinas con dominio variable dual y usos de las mismas
WO2012019168A2 (fr)	2010-08-06	2012-02-09	Moderna Therapeutics, Inc.	Acides nucléiques modifiés et leurs procédés d'utilisation
MX2013001267A (es)	2010-08-13	2013-04-10	Genentech Inc	ANTICUERPOS A IL-1ß E EIL-18 PARA TRATAMIENTO DE ENFERMEDAD.
RU2603284C2 (ru) *	2010-08-17	2016-11-27	Ф.Хоффманн-Ля Рош Аг	АНТИТЕЛА ПРОТИВ IgG1 ЧЕЛОВЕКА
TW201208703A (en)	2010-08-17	2012-03-01	Roche Glycart Ag	Combination therapy of an afucosylated CD20 antibody with an anti-VEGF antibody
WO2012027570A2 (fr)	2010-08-26	2012-03-01	Abbott Laboratories	Immunoglobulines à deux domaines variables et leurs utilisations
WO2012030512A1 (fr)	2010-09-03	2012-03-08	Percivia Llc.	Procédé de purification de protéine en flux
SG190679A1 (en)	2010-10-01	2013-07-31	Jason Schrum	Engineered nucleic acids and methods of use thereof
BR112013008765B8 (pt)	2010-10-11	2023-05-02	Biogen Idec Int Neuroscience Gmbh	Anticorpos monoclonais anti-tau humano isolados ou um fragmento de ligação à tau dos mesmos, métodos de preparação dos mesmos, polinucleotídeo ou polinucleotídeos, vetor ou vetores, composição, método in vitro de diagnóstico ou monitoramento da progressão de uma tauopatia neurodegenerativa em um indivíduo humano, método in vitro para diagnosticar uma tauopatia neurodegenerativa em um indivíduo humano, e kit útil para o diagnóstico de uma tauopatia neurodegenerativa
KR20200059320A (ko)	2010-11-08	2020-05-28	제넨테크, 인크.	피하 투여용 항―ｉｌ―6 수용체 항체
BR112013014949B1 (pt)	2010-12-15	2021-12-28	Inter-University Research Institute Corporation Research Organization Of Information And Systems	Métodos para a produção de uma proteína de interesse e para a obtenção de uma suspensão de células cho capaz de sobreviver e proliferar em um meio sem soro que produz uma proteína de interesse
CA2819436A1 (fr)	2010-12-16	2012-06-21	Roche Glycart Ag	Therapie d'association d'un anticorps cd20 afucosyle avec un inhibiteur mdm2
EP3628689A1 (fr)	2010-12-17	2020-04-01	Neurimmune Holding AG	Anticorps anti-sod1 humains
EP2655417A2 (fr)	2010-12-21	2013-10-30	AbbVie Inc.	Il-1-alpha et bêta bispecifique immunoglobulines de domaine variable et leur utilisation
EP3147355B1 (fr)	2010-12-27	2020-07-22	Kyowa Kirin Co., Ltd.	Procédé de préparation d'une solution aqueuse contenant un milieu de culture et un agent chélatant
WO2012095514A1 (fr)	2011-01-14	2012-07-19	Vivalis	Système de production de protéines recombinantes
WO2012106368A2 (fr)	2011-01-31	2012-08-09	The Regents Of The University Of California	Procédés d'inhibition du cancer de la prostate
WO2012118750A2 (fr)	2011-02-28	2012-09-07	Genentech, Inc.	Marqueurs biologiques et procédés de prédiction de réponse à des antagonistes de lymphocytes b
TWI803876B (zh)	2011-03-28	2023-06-01	法商賽諾菲公司	具有交叉結合區定向之雙重可變區類抗體結合蛋白
BR112013024574B1 (pt)	2011-03-29	2022-08-09	Roche Glycart Ag	Anticorpo e uso do anticorpo
US8710200B2 (en)	2011-03-31	2014-04-29	Moderna Therapeutics, Inc.	Engineered nucleic acids encoding a modified erythropoietin and their expression
EP2506015A1 (fr)	2011-04-01	2012-10-03	Universität Regensburg	Signature pronostique et thérapeutique pour le mélanome malin
EP3536708A1 (fr)	2011-04-19	2019-09-11	Pfizer Inc	Combinaisons d'anticorps anti-4-1bb et d'anticorps induisant une cytotoxicité à médiation cellulaire dépendante d'un anticorps (adcc) pour le traitement du cancer
HUE048876T2 (hu)	2011-05-09	2020-08-28	Mayo Found Medical Education & Res	Rákos megbetegedések kezelése
JP5987053B2 (ja)	2011-05-12	2016-09-06	ジェネンテック，インコーポレイテッド	フレームワークシグネチャーペプチドを用いて動物サンプルにおける治療抗体を検出するための多重反応モニタリングｌｃ−ｍｓ／ｍｓ法
CN107903325B (zh)	2011-05-16	2021-10-29	埃泰美德(香港)有限公司	多特异性fab融合蛋白及其使用方法
SG10201703425RA (en)	2011-05-21	2017-05-30	Macrogenics Inc	Cd3-binding molecules capable of binding to human and non-human cd3
EP2714079B2 (fr)	2011-05-21	2019-08-28	MacroGenics, Inc.	Domaines de liaison du sérum déimmunisé et leur utilisation pour prolonger la demi-vie du sérum
RU2011122942A (ru)	2011-06-08	2012-12-20	Общество С Ограниченной Ответственностью "Асинэкс Медхим"	Новые ингибиторы киназ
EP2723379B1 (fr)	2011-06-23	2018-09-12	Biogen International Neuroscience GmbH	Molécules de liaison anti-alpha-synucléine
EP2537933A1 (fr)	2011-06-24	2012-12-26	Institut National de la Santé et de la Recherche Médicale (INSERM)	Immunocytokines basées sur le domaine IL-15 et IL-15Ralpha sushi
AU2012280267B2 (en)	2011-07-06	2016-04-21	Morphosys Ag	Therapeutic combinations of anti-cd20 and anti-gm-csf antibodies and uses thereof
EP2732021B1 (fr)	2011-07-08	2020-05-27	EMD Millipore Corporation	Filtres en profondeur jetables améliorés pour processus biotechnologiques
US9464288B2 (en)	2011-07-11	2016-10-11	Yale University	Compositions and methods for making selenocysteine containing polypeptides
WO2019071023A1 (fr)	2017-10-04	2019-04-11	Yale University	Compositions et procédés de fabrication de polypeptides contenant de la sélénocystéine
US9738707B2 (en)	2011-07-15	2017-08-22	Biogen Ma Inc.	Heterodimeric Fc regions, binding molecules comprising same, and methods relating thereto
EP2550975A1 (fr)	2011-07-29	2013-01-30	Sanofi	Polythérapie pour le traitement de symptômes de malignités CD19+lymphocytes B comprenant un immunoconjugué anti-CD19 maytansinoïde et du rituximab
EP2551348B1 (fr)	2011-07-29	2014-09-24	Icon Genetics GmbH	Production de N-glycanes galactosylatées dans des plantes
WO2013022855A1 (fr)	2011-08-05	2013-02-14	Xencor, Inc.	Anticorps avec points isoélectriques modifiés et immunofiltration
US9464124B2 (en)	2011-09-12	2016-10-11	Moderna Therapeutics, Inc.	Engineered nucleic acids and methods of use thereof
US20140234307A1 (en)	2011-09-27	2014-08-21	The United States Of America,As Represented By The Secretary,Department Of Health And Human Services	Method of treating multiple sclerosis by intrathecal depletion of b cells and biomarkers to select patients with progressive multiple sclerosis
RU2707251C2 (ru)	2011-10-03	2019-11-25	Модерна Терапьютикс, Инк.	Модифицированные нуклеозиды, нуклеотиды и нуклеиновые кислоты и их применение
AU2012320847B2 (en)	2011-10-04	2018-03-08	Icon Genetics Gmbh	Nicotiana benthamiana plants deficient in fucosyltransferase activity
CA2851534C (fr)	2011-10-10	2023-02-14	Xencor, Inc.	Procede de purification d'anticorps
US10851178B2 (en)	2011-10-10	2020-12-01	Xencor, Inc.	Heterodimeric human IgG1 polypeptides with isoelectric point modifications
EP2771360A1 (fr)	2011-10-24	2014-09-03	AbbVie Inc.	Agents de liaison immunologique dirigés contre la sclérostine
US9790280B2 (en)	2011-10-26	2017-10-17	Elanco Tiergesundheit Ag	Monoclonal canine CD20 antibodies and methods of use
US20130302274A1 (en)	2011-11-25	2013-11-14	Roche Glycart Ag	Combination therapy
WO2013090648A1 (fr)	2011-12-16	2013-06-20	modeRNA Therapeutics	Nucléoside, nucléotide, et compositions d'acide nucléique modifiés
CN104125963B (zh)	2011-12-22	2018-08-17	弗·哈夫曼-拉罗切有限公司	使用离子交换膜层析改进下游蛋白质纯化步骤的方法
US9120870B2 (en)	2011-12-30	2015-09-01	Abbvie Inc.	Dual specific binding proteins directed against IL-13 and IL-17
TW201334789A (zh)	2012-01-31	2013-09-01	Genentech Inc	抗ｉｇｅ抗體及其使用方法
WO2013123432A2 (fr)	2012-02-16	2013-08-22	Atyr Pharma, Inc.	Histidyl-arnt synthétases pour le traitement de maladies auto-immunes et inflammatoires
WO2013148249A1 (fr)	2012-03-27	2013-10-03	Genentech, Inc.	Opérations de récolte améliorées pour protéines recombinées
US9254311B2 (en)	2012-04-02	2016-02-09	Moderna Therapeutics, Inc.	Modified polynucleotides for the production of proteins
US9283287B2 (en)	2012-04-02	2016-03-15	Moderna Therapeutics, Inc.	Modified polynucleotides for the production of nuclear proteins
JP2015513913A (ja)	2012-04-02	2015-05-18	モデルナセラピューティクスインコーポレイテッドＭｏｄｅｒｎａＴｈｅｒａｐｅｕｔｉｃｓ，Ｉｎｃ．	修飾ポリヌクレオチド
US9572897B2 (en)	2012-04-02	2017-02-21	Modernatx, Inc.	Modified polynucleotides for the production of cytoplasmic and cytoskeletal proteins
US10130714B2 (en)	2012-04-14	2018-11-20	Academia Sinica	Enhanced anti-influenza agents conjugated with anti-inflammatory activity
CA2873623C (fr)	2012-05-14	2021-11-09	Biogen Idec Ma Inc.	Antagonistes de lingo-2 pour le traitement d'affections impliquant des neurones moteurs
EP2863940A4 (fr)	2012-06-08	2016-08-10	Biogen Ma Inc	Facteurs de coagulation chimériques
EP3505534A1 (fr)	2012-06-08	2019-07-03	Sutro Biopharma, Inc.	Anticorps comprenant des résidus d'acides aminés non endogènes spécifiques d'un site, leurs procédés de préparation et leurs procédés d'utilisation
WO2014011955A2 (fr)	2012-07-12	2014-01-16	Abbvie, Inc.	Protéines de liaison à il-1
SMT202100621T1 (it)	2012-07-13	2022-01-10	Roche Glycart Ag	Anticorpi bispecifici anti-vegf/anti-ang-2 e loro impiego nel trattamento delle malattie vascolari oculari
JP6302909B2 (ja)	2012-08-18	2018-03-28	アカデミアシニカＡｃａｄｅｍｉａＳｉｎｉｃａ	シアリダーゼの同定および画像化のための細胞透過性プローブ
AU2013305827A1 (en)	2012-08-21	2015-03-05	Academia Sinica	Benzocyclooctyne compounds and uses thereof
CN104981254B (zh)	2012-08-31	2018-05-22	苏特罗生物制药公司	含有叠氮基的经修饰的氨基酸
JOP20200236A1 (ar)	2012-09-21	2017-06-16	Regeneron Pharma	الأجسام المضادة لمضاد cd3 وجزيئات ربط الأنتيجين ثنائية التحديد التي تربط cd3 وcd20 واستخداماتها
WO2014052713A2 (fr)	2012-09-27	2014-04-03	Massachusetts Institute Of Technology	Protéines de liaison à her2 et vegf-a à stabilité améliorée
AU2013327638B2 (en)	2012-10-01	2018-06-14	Mayo Foundation For Medical Education And Research	Cancer treatments
EP2906240A2 (fr)	2012-10-09	2015-08-19	Biogen MA Inc.	Polythérapies et leurs utilisations pour le traitement de troubles de la démyélinisation
MX338711B (es)	2012-10-12	2016-04-28	Medimmune Ltd	Pirrolobenzodiazepinas y conjugados de las mismas.
US9163093B2 (en)	2012-11-01	2015-10-20	Abbvie Inc.	Anti-DLL4/VEGF dual variable domain immunoglobulin and uses thereof
CA2889488A1 (fr)	2012-11-01	2014-05-08	Abbvie Inc.	Formulations de proteine immunoglobuline a domaine variable double stable
SI3150256T1 (sl)	2012-11-02	2021-03-31	Tg Therapeutics Inc.	Kombinacija anti-CD20 protitelesa in selektivnega inhibitorja PI3 kinaze
JP6144355B2 (ja)	2012-11-26	2017-06-07	モデルナティエックスインコーポレイテッドＭｏｄｅｒｎａＴＸ，Ｉｎｃ．	化学修飾ｍＲＮＡ
US9393327B2 (en)	2012-12-19	2016-07-19	Genentech, Inc.	Methods and compositions for radiohalogen protein labeling
BR112015014751A8 (pt)	2012-12-21	2018-01-16	Biogen Int Neuroscience Gmbh	anti-corpos anti-tau humanos e fragmento de ligação a tau dos mesmo, seu uso na preparação de um medicamento, bem como polipeptídeos codificando os mesmos.
WO2014102399A1 (fr)	2012-12-31	2014-07-03	Neurimmune Holding Ag	Anticorps humains recombinants destinés à la thérapie et à la prévention de maladies associées aux polyomavirus
US11053316B2 (en)	2013-01-14	2021-07-06	Xencor, Inc.	Optimized antibody variable regions
US10131710B2 (en)	2013-01-14	2018-11-20	Xencor, Inc.	Optimized antibody variable regions
US9701759B2 (en)	2013-01-14	2017-07-11	Xencor, Inc.	Heterodimeric proteins
AU2014205086B2 (en)	2013-01-14	2019-04-18	Xencor, Inc.	Novel heterodimeric proteins
US10487155B2 (en)	2013-01-14	2019-11-26	Xencor, Inc.	Heterodimeric proteins
US9605084B2 (en)	2013-03-15	2017-03-28	Xencor, Inc.	Heterodimeric proteins
US10968276B2 (en)	2013-03-12	2021-04-06	Xencor, Inc.	Optimized anti-CD3 variable regions
AU2014207549B2 (en)	2013-01-15	2018-12-06	Xencor, Inc.	Rapid clearance of antigen complexes using novel antibodies
SG11201505663YA (en)	2013-01-24	2015-08-28	Scripps Korea Antibody Inst	Protein combination-based fv library, and preparation method therefor
AU2014214843A1 (en)	2013-02-07	2015-05-21	Immunomedics, Inc.	Pro-drug form (P2PDox) of the highly potent 2-pyrrolinodoxorubicin conjugated to antibodies for targeted therapy of cancer
ES2959747T3 (es)	2013-02-15	2024-02-28	Bioverativ Therapeutics Inc	Gen del factor VIII optimizado
US9487587B2 (en)	2013-03-05	2016-11-08	Macrogenics, Inc.	Bispecific molecules that are immunoreactive with immune effector cells of a companion animal that express an activating receptor and cells that express B7-H3 and uses thereof
WO2014140174A1 (fr)	2013-03-13	2014-09-18	Spirogen Sàrl	Pyrrolobenzodiazépines et leurs conjugués
AU2014243783B2 (en)	2013-03-13	2018-12-13	Genentech, Inc.	Antibody formulations
WO2014159940A1 (fr)	2013-03-14	2014-10-02	Macrogenics, Inc.	Molécules bispécifiques immunoréactives à des cellules effectrices immunitaires exprimant un récepteur d'activation
AU2014232416B2 (en)	2013-03-15	2017-09-28	Xencor, Inc.	Modulation of T Cells with Bispecific Antibodies and FC Fusions
US8980864B2 (en)	2013-03-15	2015-03-17	Moderna Therapeutics, Inc.	Compositions and methods of altering cholesterol levels
US10106624B2 (en)	2013-03-15	2018-10-23	Xencor, Inc.	Heterodimeric proteins
WO2014144549A1 (fr)	2013-03-15	2014-09-18	Biogen Idec Ma Inc.	Préparations contenant un polypeptide du facteur ix
US10858417B2 (en)	2013-03-15	2020-12-08	Xencor, Inc.	Heterodimeric proteins
US9062108B2 (en)	2013-03-15	2015-06-23	Abbvie Inc.	Dual specific binding proteins directed against IL-1 and/or IL-17
JP6449229B2 (ja)	2013-03-15	2019-01-09	アッヴィ・バイオセラピューティクス・インコーポレイテッド	Ｆｃ変異体
US10519242B2 (en)	2013-03-15	2019-12-31	Xencor, Inc.	Targeting regulatory T cells with heterodimeric proteins
US20160030384A1 (en)	2013-04-09	2016-02-04	Boston Biomedical, Inc.	2-acetylnaphtho[2,3-b]furan -4,9-dione for use on treating cancer
HUE058364T2 (hu)	2013-04-19	2022-07-28	Cytune Pharma	Citokinbõl származó kezelés redukált vaszkuláris permeabilitási szindrómával
EP2805730A1 (fr)	2013-05-21	2014-11-26	Bergen Teknologioverforing AS	Donneurs d'oxyde nitrique pour le traitement du syndrome de fatigue chronique
KR102332303B1 (ko)	2013-05-31	2021-11-26	자임워크스 인코포레이티드	감소되거나 침묵화된 효과기 기능을 갖는 이종다량체
US10086054B2 (en)	2013-06-26	2018-10-02	Academia Sinica	RM2 antigens and use thereof
EP3013347B1 (fr)	2013-06-27	2019-12-11	Academia Sinica	Conjugués de glycane et leur utilisation
ES2658039T3 (es)	2013-07-10	2018-03-08	Sutro Biopharma, Inc.	Anticuerpos que comprenden múltiples residuos de aminoácidos no naturales sitio-específicos, métodos para su preparación y métodos de uso
US11384149B2 (en)	2013-08-09	2022-07-12	Macrogenics, Inc.	Bi-specific monovalent Fc diabodies that are capable of binding CD32B and CD79b and uses thereof
UA116479C2 (uk)	2013-08-09	2018-03-26	Макродженікс, Інк.	БІСПЕЦИФІЧНЕ МОНОВАЛЕНТНЕ Fc-ДІАТІЛО, ЯКЕ ОДНОЧАСНО ЗВ'ЯЗУЄ CD32B I CD79b, ТА ЙОГО ЗАСТОСУВАННЯ
EP2840091A1 (fr)	2013-08-23	2015-02-25	MacroGenics, Inc.	Diabody se liant specifiquement a l'antigene gpA33 et CD3 et procedes d'utilisation
EP2839842A1 (fr)	2013-08-23	2015-02-25	MacroGenics, Inc.	Bianticorps monovalents bi-spécifiques capables de se lier aux CD123 et CD3 et leurs utilisations
WO2015035044A2 (fr)	2013-09-04	2015-03-12	Abbvie Biotherapeutics Inc.	Variants fc présentant une cytotoxicité cellulaire dépendante des anticorps améliorée
JP6486368B2 (ja)	2013-09-06	2019-03-20	アカデミアシニカＡｃａｄｅｍｉａＳｉｎｉｃａ	改変されたグリコシル基を含む糖脂質を用いたヒトｉＮＫＴ細胞の活性化
IL312865B1 (en)	2013-09-11	2025-02-01	Eagle Biologics Inc	Liquid protein formulations containing viscosity-reducing agents
EP3052106A4 (fr)	2013-09-30	2017-07-19	ModernaTX, Inc.	Polynucléotides codant des polypeptides de modulation immunitaire
CN105980401A (zh)	2013-10-03	2016-09-28	现代治疗公司	编码低密度脂蛋白受体的多核苷酸
US9840493B2 (en)	2013-10-11	2017-12-12	Sutro Biopharma, Inc.	Modified amino acids comprising tetrazine functional groups, methods of preparation, and methods of their use
US20160256460A1 (en)	2013-11-01	2016-09-08	Bergen Teknologioverføring As	Activators or stimulators of soluble guanylate cyclase for use in treating chronic fatigue syndrome
CN106414494B (zh)	2013-11-12	2020-09-18	Ogd2药物	具有促凋亡活性的人IgG1衍生的抗体
KR20160089532A (ko)	2013-12-17	2016-07-27	제넨테크, 인크.	Pd-1 축 결합 길항제 및 항-cd20 항체를 사용하여 암을 치료하는 방법
US10150818B2 (en)	2014-01-16	2018-12-11	Academia Sinica	Compositions and methods for treatment and detection of cancers
CN106459920B (zh)	2014-01-16	2020-10-30	中央研究院	治疗及检测癌症的组合物及方法
EP3110445A4 (fr)	2014-02-25	2017-09-27	Immunomedics, Inc.	Anticorps rfb4 humanisés anti-cd22
EP2915569A1 (fr)	2014-03-03	2015-09-09	Cytune Pharma	Procédé de purification de conjugués à base Il -15/IL-15Ralpha
TWI701042B (zh)	2014-03-19	2020-08-11	美商再生元醫藥公司	用於腫瘤治療之方法及抗體組成物
JP6562942B2 (ja)	2014-03-27	2019-08-28	アカデミアシニカＡｃａｄｅｍｉａＳｉｎｉｃａ	反応性標識化合物およびその使用
WO2015149077A1 (fr)	2014-03-28	2015-10-01	Xencor, Inc.	Anticorps bispécifiques se liant à cd38 et cd3
SG11201608862SA (en)	2014-04-23	2016-11-29	Juno Therapeutics Inc	Methods for isolating, culturing, and genetically engineering immune cell populations for adoptive therapy
US20170049887A1 (en)	2014-04-25	2017-02-23	University Of Florida Research Foundation, Inc.	Methods of permitting a subject to receive multiple doses of recombinant adeno-associated virus
US10118969B2 (en)	2014-05-27	2018-11-06	Academia Sinica	Compositions and methods relating to universal glycoforms for enhanced antibody efficacy
CA2950440A1 (fr)	2014-05-27	2015-12-03	Academia Sinica	Glycoanticorps anti-her2 et leurs utilisations
CA2950415A1 (fr)	2014-05-27	2015-12-03	Academia Sinica	Glycoanticorps anti-cd20 et leurs utilisations
JP6894239B2 (ja)	2014-05-27	2021-06-30	アカデミアシニカＡｃａｄｅｍｉａＳｉｎｉｃａ	増強された抗体の有効性のための普遍的グリコフォームに関する組成物および方法
EP3154582A4 (fr)	2014-05-28	2018-01-10	Academia Sinica	Glycoanticorps anti-thf-alpha et leurs utilisations
US20160250351A1 (en)	2014-06-13	2016-09-01	Mayo Foundation For Medical Education And Research	Treating Lymphomas
CN113134095A (zh)	2014-06-16	2021-07-20	梅约医学教育与研究基金会	治疗骨髓瘤
WO2016004113A1 (fr)	2014-06-30	2016-01-07	Biogen Ma Inc.	Gène du facteur ix optimisé
EP3166401B1 (fr)	2014-07-09	2020-08-19	F. Hoffmann-La Roche AG	Réglage de ph pour améliorer la récupération par décongélation de banques de cellules
CA2954738A1 (fr)	2014-07-29	2016-02-04	Neurimmune Holding Ag	Anticorps anti-huntingtine (htt) humains et leurs utilisations
AU2015315294B2 (en)	2014-09-08	2020-09-17	Academia Sinica	Human iNKT cell activation using glycolipids
CN106687141A (zh)	2014-09-10	2017-05-17	麦迪穆有限责任公司	吡咯并苯并二氮杂卓及其缀合物
WO2016037947A1 (fr)	2014-09-10	2016-03-17	F. Hoffmann-La Roche Ag	Anticorps de type immunoglobulines 1 galacto-modifiés
JP7072384B2 (ja)	2014-09-15	2022-05-20	ジェネンテック，インコーポレイテッド	抗体製剤
PL3262071T3 (pl)	2014-09-23	2020-08-10	F. Hoffmann-La Roche Ag	Sposób stosowania immunokoniugatów anty-CD79b
EP3201227A4 (fr)	2014-09-29	2018-04-18	Duke University	Molécules bispécifiques comprenant un bras de ciblage d'enveloppe du vih-1
BR112017006598A2 (pt)	2014-09-30	2018-04-17	Neurimmune Holding Ag	anticorpo de repetições antidipeptídeo derivado de ser humano (dprs)
SG11201702614SA (en)	2014-10-01	2017-04-27	Eagle Biolog Inc	Polysaccharide and nucleic acid formulations containing viscosity-lowering agents
US9446148B2 (en)	2014-10-06	2016-09-20	Mayo Foundation For Medical Education And Research	Carrier-antibody compositions and methods of making and using the same
MA40835A (fr)	2014-10-23	2017-08-29	Biogen Ma Inc	Anticorps anti-gpiib/iiia et leurs utilisations
MA40861A (fr)	2014-10-31	2017-09-05	Biogen Ma Inc	Anticorps anti-glycoprotéines iib/iiia
HUE050831T2 (hu)	2014-11-17	2021-01-28	Regeneron Pharma	Daganatkezelési módszerek a CD3XCD20 bispecifikus antitest használatával
WO2016086196A2 (fr)	2014-11-26	2016-06-02	Xencor, Inc.	Anticorps hétérodimériques se liant aux antigènes cd3 et cd38
US10259887B2 (en)	2014-11-26	2019-04-16	Xencor, Inc.	Heterodimeric antibodies that bind CD3 and tumor antigens
CN113735976A (zh)	2014-11-26	2021-12-03	森科股份有限公司	结合cd3和肿瘤抗原的异二聚体抗体
WO2016094881A2 (fr)	2014-12-11	2016-06-16	Abbvie Inc.	Protéines de liaison à lrp-8
US10428155B2 (en)	2014-12-22	2019-10-01	Xencor, Inc.	Trispecific antibodies
WO2016112270A1 (fr)	2015-01-08	2016-07-14	Biogen Ma Inc.	Antagonistes de lingo-1 et leurs utilisations pour le traitement de troubles de démyélinisation
US10495645B2 (en)	2015-01-16	2019-12-03	Academia Sinica	Cancer markers and methods of use thereof
US9975965B2 (en)	2015-01-16	2018-05-22	Academia Sinica	Compositions and methods for treatment and detection of cancers
US10342858B2 (en)	2015-01-24	2019-07-09	Academia Sinica	Glycan conjugates and methods of use thereof
US10227411B2 (en)	2015-03-05	2019-03-12	Xencor, Inc.	Modulation of T cells with bispecific antibodies and FC fusions
WO2016149485A1 (fr)	2015-03-17	2016-09-22	The Regents Of The University Of California	Nouvelle chimio-immunothérapie pour cancer épithélial
CN107667120B (zh)	2015-03-17	2022-03-08	纪念斯隆-凯特林癌症中心	抗muc16抗体及其应用
JP6963508B2 (ja)	2015-05-11	2021-11-10	ジェネンテック，インコーポレイテッド	ループス腎炎を治療する組成物及び方法
CN107849096B (zh)	2015-05-30	2022-05-24	分子模板公司	去免疫化的志贺毒素a亚基支架和包含它们的细胞靶向分子
US20180140572A1 (en)	2015-06-03	2018-05-24	Boston Biomedical, Inc.	Compositions comprising a cancer stemness inhibitor and an immunotherapeutic agent for use in treating cancer
TW201710286A (zh)	2015-06-15	2017-03-16	艾伯維有限公司	抗ｖｅｇｆ、ｐｄｇｆ及／或其受體之結合蛋白
EP3108897A1 (fr)	2015-06-24	2016-12-28	F. Hoffmann-La Roche AG	Anticorps contre le csf-1r humain permettant d'induire une lymphocytose dans les lymphomes ou les leucémies
KR20180020169A (ko)	2015-06-24	2018-02-27	에프. 호프만-라 로슈 아게	조정된 친화도를 갖는 항-트랜스페린 수용체 항체
EP3313885A1 (fr)	2015-06-29	2018-05-02	H. Hoffnabb-La Roche Ag	Anticorps anti-cd20 de type ii destiné à une utilisation dans la transplantation d'organes
BR112018002150A2 (pt)	2015-08-03	2018-09-18	Bioverativ Therapeutics Inc	proteínas de fusão do fator ix e métodos de fabricação e uso das mesmas
JP6889149B2 (ja)	2015-08-13	2021-06-18	アムジエン・インコーポレーテツド	抗原結合タンパク質の荷電深層ろ過
TW201707725A (zh)	2015-08-18	2017-03-01	美國馬友醫藥教育研究基金會	載體－抗體組合物及其製造及使用方法
TWI744247B (zh)	2015-08-28	2021-11-01	美商亞穆尼克斯製藥公司	嵌合多肽組合體以及其製備及使用方法
MX2018003292A (es)	2015-09-21	2018-08-01	Aptevo Res & Development Llc	Polipéptidos de unión a cd3.
AR106189A1 (es)	2015-10-02	2017-12-20	Hoffmann La Roche	ANTICUERPOS BIESPECÍFICOS CONTRA EL A-b HUMANO Y EL RECEPTOR DE TRANSFERRINA HUMANO Y MÉTODOS DE USO
CR20180149A (es)	2015-10-02	2018-04-05	Hoffmann La Roche	Anticuerpos biespecíficos contra el cd20 humano y el receptor de transferrina humano y métodos de uso
TW201713360A (en)	2015-10-06	2017-04-16	Mayo Foundation	Methods of treating cancer using compositions of antibodies and carrier proteins
KR102714709B1 (ko)	2015-11-02	2024-10-07	바이오아트라, 인코퍼레이티드	조건부 활성 폴리펩티드
WO2017100372A1 (fr)	2015-12-07	2017-06-15	Xencor, Inc.	Anticorps hétérodimèes se liant à cd3 et psma
EP3397287A1 (fr)	2015-12-30	2018-11-07	Genentech, Inc.	Formulations présentant une moindre dégradation des polysorbates
EP3399861A4 (fr)	2016-01-07	2019-08-07	Mayo Foundation for Medical Education and Research	Procédés de traitement du cancer par interféron
EP3411478B1 (fr)	2016-02-01	2022-06-08	Bioverativ Therapeutics Inc.	Gènes du facteur viii optimisés
WO2017139698A1 (fr)	2016-02-12	2017-08-17	Mayo Foundation For Medical Education And Research	Traitements des cancers hématologiques
EP3423490A1 (fr)	2016-03-01	2019-01-09	H. Hoffnabb-La Roche Ag	Variants de l'obinutuzumab et du rituximab liés à une moindre phagocytose dépendante des anticorps (adcp)
EP3423593A1 (fr)	2016-03-02	2019-01-09	Institut National de la Sante et de la Recherche Medicale (INSERM)	Procédés et kits de prédiction du risque de rechute chez des patients souffrant d'un syndrome néphrotique idiopathique
EP3426693A4 (fr)	2016-03-08	2019-11-13	Academia Sinica	Procédés de synthèse modulaire de n-glycanes et de puces à n-glycanes
MY195541A (en)	2016-03-14	2023-01-31	Univ Oslo	Engineered Immunoglobulins With Altered Fcrn Binding
CN109476756B (zh)	2016-03-15	2022-05-31	埃泰美德(香港)有限公司	一种多特异性Fab融合蛋白及其用途
AU2017238118A1 (en)	2016-03-21	2018-10-11	Mayo Foundation For Medical Education And Research	Methods for improving the therapeutic index for a chemotherapeutic drug
US11305020B2 (en)	2016-03-21	2022-04-19	Mayo Foundation For Medical Education And Research	Methods for reducing toxicity of a chemotherapeutic drug
JP2019510517A (ja)	2016-03-29	2019-04-18	ジェルター，インコーポレイテッド	細胞質内体積に対するペリプラズム体積の比率が０．５：１および１０：１の間にあるグラム陰性細菌におけるタンパク質の発現
US10618969B2 (en)	2016-04-06	2020-04-14	Mayo Foundation For Medical Education And Research	Carrier-binding agent compositions and methods of making and using the same
CR20180484A (es)	2016-04-15	2019-03-05	Macrogenics Inc	Moléculas de unón b7-h3 novedosas, conjugados anticuerpos-fármaco de los mismos y métodos de uso de los mismos
JP2019514870A (ja)	2016-04-22	2019-06-06	アンスティチュナショナルドゥラサンテエドゥラルシェルシュメディカル	Ｂ細胞悪性腫瘍の処置のための方法及びワクチン組成物
KR20190015351A (ko)	2016-05-27	2019-02-13	티지 쎄라퓨틱스, 인코포레이티드	B-세포 증식성 장애를 치료하기 위한 항-cd20 항체, p13 키나제-델타 선택적 억제제 및 btk 억제제의 조합
RU2767357C2 (ru)	2016-06-14	2022-03-17	Ксенкор, Инк.	Биспецифические антитела-ингибиторы контрольных точек
EP3472197A1 (fr)	2016-06-15	2019-04-24	Sutro Biopharma, Inc.	Anticorps à domaines ch2 modifiés, compositions les contenant et leurs procédés d'utilisation
EP3475304B1 (fr)	2016-06-28	2022-03-23	Xencor, Inc.	Anticorps hétérodimériques qui se lient au récepteur 2 de la somatostatine
MA45668A (fr)	2016-07-13	2019-05-22	Biogen Ma Inc	Schémas posologiques d'antagonistes de lingo-1 et leurs utilisations pour le traitement de troubles de démyélinisation
JP2018035137A (ja)	2016-07-13	2018-03-08	マブイミューンダイアグノスティックスエイジーＭａｂｉｍｍｕｎｅＤｉａｇｎｏｓｔｉｃｓＡｇ	新規な抗線維芽細胞活性化タンパク質（ｆａｐ）結合薬剤およびその使用
GB201613167D0 (en)	2016-07-29	2016-09-14	Univ Southampton	Cancer and b-cell related disease therapy
TWI764917B (zh)	2016-08-22	2022-05-21	醣基生醫股份有限公司	抗體、結合片段及使用方法
US10793632B2 (en)	2016-08-30	2020-10-06	Xencor, Inc.	Bispecific immunomodulatory antibodies that bind costimulatory and checkpoint receptors
CN107384932B (zh)	2016-08-31	2020-10-20	北京天广实生物技术股份有限公司	抗人cd20人源化单克隆抗体mil62、其制备方法及用途
KR20190053203A (ko)	2016-09-01	2019-05-17	메이오 파운데이션 포 메디칼 에쥬케이션 앤드 리써치	Ｔ－세포 암을 표적화하는 방법 및 조성물
KR20220151022A (ko)	2016-09-01	2022-11-11	메이오 파운데이션 포 메디칼 에쥬케이션 앤드 리써치	암 치료용 담체－ｐｄ－ｌ１ 결합제 조성물
WO2018048815A1 (fr)	2016-09-06	2018-03-15	Nantibodyfc, Llc	Méthodes de traitement d'un cancer du sein triple-négatif à l'aide de compositions d'anticorps et de protéines porteuses
AU2017324335A1 (en)	2016-09-06	2019-03-28	Mayo Foundation For Medical Education And Research	Methods of treating PD-L1 expressing cancer
WO2018048958A1 (fr)	2016-09-06	2018-03-15	Mayo Foundation For Medical Education And Research	Compositions d'agents de liaison, de paclitaxel et d'albumine et leurs procédés d'utilisation et de production
AU2017322501A1 (en)	2016-09-09	2019-03-28	Laboratoire Francais Du Fractionnement Et Des Biotechnologies	Combination of an anti-CD20 antibody, PI3 kinase-delta inhibitor, and anti-PD-1 or anti-PD-L1 antibody for treating hematological cancers
CN108421048B (zh) *	2016-09-28	2021-04-20	首都医科大学附属北京世纪坛医院	纳米活性碳靶向药物递送系统、制备方法及其用途
US20200023072A1 (en)	2016-10-11	2020-01-23	Medimmune Limited	Antibody-drug conjugates with immune-mediated therapy agents
KR102562519B1 (ko)	2016-10-14	2023-08-02	젠코어 인코포레이티드	IL-15/IL-15Rα FC-융합 단백질 및 PD-1 항체 단편을 포함하는 이중특이성 이종이량체 융합 단백질
AU2017364077A1 (en)	2016-11-22	2019-06-20	Elektrofi, Inc.	Particles comprising a therapeutic or diagnostic agent and suspensions and methods of use thereof
WO2018102427A1 (fr)	2016-11-29	2018-06-07	Boston Biomedical, Inc.	Dérivés de naphthofurane, préparation et procédés d'utilisation associés
WO2018100096A1 (fr)	2016-12-01	2018-06-07	Inserm (Institut National De La Sante Et De La Recherche Medicale)	Utilisation de la concentration plasmatique d'igg anti-uchl1 pour diagnostiquer le syndrome néphrotique idiopathique sensible aux stéroïdes
KR20190091292A (ko)	2016-12-02	2019-08-05	바이오버라티브 테라퓨틱스 인크.	응고 인자에 대한 면역 내성 유도 방법
IL308416A (en)	2016-12-02	2024-01-01	Bioverativ Therapeutics Inc	Methods for the treatment of hemophilic arthritis with the help of chimeric blood coagulation factors
MA47416A (fr)	2017-01-31	2019-12-11	Bioverativ Therapeutics Inc	Protéine de fusion du facteur ix et procédés de fabrication et d'utilisation associés
GB201703876D0 (en)	2017-03-10	2017-04-26	Berlin-Chemie Ag	Pharmaceutical combinations
WO2018187074A1 (fr)	2017-04-03	2018-10-11	Immunomedics, Inc.	Administration par voie sous-cutanée de conjugués anticorps-médicament à titre de thérapie anticancéreuse
EP3624846B1 (fr)	2017-05-16	2024-08-07	Bhami's Research Laboratory, Pvt. Ltd.	Formulations de protéines à haute concentration ayant une viscosité réduite incluant une mixture d'acide nicotinique et tryoptophane
CA3062656A1 (fr)	2017-05-17	2018-11-22	Boston Biomedical, Inc.	Methodes pour le traitement du cancer
EP3645122A1 (fr)	2017-06-30	2020-05-06	Xencor, Inc.	Protéines de fusion fc hétérodimères ciblées contenant il-15/il-15ra et domaines de liaison à l'antigène
WO2019011918A1 (fr)	2017-07-10	2019-01-17	International - Drug - Development - Biotech	Traitement de malignités de lymphocytes b à l'aide d'anticorps anti-cd19 pro-apoptotiques afucosylés en combinaison avec des anticorps anti-cd20 ou des agents chimiothérapeutiques
EP3658584A1 (fr)	2017-07-26	2020-06-03	H. Hoffnabb-La Roche Ag	Polythérapie avec un inhibiteur bet, un inhibiteur bcl-2 et un anticorps anti-cd20
JP7374883B2 (ja)	2017-08-09	2023-11-07	バイオベラティブセラピューティクスインコーポレイテッド	核酸分子およびその使用
US10759865B2 (en)	2017-08-22	2020-09-01	Eyal Levit	Treatment of diabetes mellitus
US11180541B2 (en)	2017-09-28	2021-11-23	Geltor, Inc.	Recombinant collagen and elastin molecules and uses thereof
WO2019077123A1 (fr)	2017-10-20	2019-04-25	INSERM (Institut National de la Santé et de la Recherche Médicale)	Procédés et kits pour identifier si un sujet est atteint ou risque d'être atteint d'une myopathie auto-immune
US10981992B2 (en)	2017-11-08	2021-04-20	Xencor, Inc.	Bispecific immunomodulatory antibodies that bind costimulatory and checkpoint receptors
EP3706793A1 (fr)	2017-11-08	2020-09-16	Xencor, Inc.	Anticorps bispécifiques et monospécifiques utilisant de nouvelles séquences anti-pd-1
IL275426B1 (en)	2017-12-19	2024-11-01	Xencor Inc	Engineered il-2 fc fusion proteins
BR112020015568A2 (pt)	2018-03-13	2020-12-29	F. Hoffmann-La Roche Ag	Agonista de 4-1bb (cd137), produto farmacêutico, composição farmacêutica, uso de uma combinação de um agonista de 4-1bb e método para tratar ou retardar a progressão do câncer
CN112154153A (zh)	2018-03-28	2020-12-29	百时美施贵宝公司	白介素-2/白介素-2受体α融合蛋白以及使用方法
US10982006B2 (en)	2018-04-04	2021-04-20	Xencor, Inc.	Heterodimeric antibodies that bind fibroblast activation protein
KR20210003814A (ko)	2018-04-18	2021-01-12	젠코어 인코포레이티드	IL-15/IL-15Rα Fc-융합 단백질 및 TIM-3 항원 결합 도메인을 함유하는 TIM-3 표적화 이종이량체 융합 단백질
CN112334571B (zh)	2018-04-18	2024-06-25	Ucl商业有限公司	工程化的调节性t细胞
MX2020010910A (es)	2018-04-18	2021-02-09	Xencor Inc	Proteinas de fusion heterodimericas dirigidas a pd-1 que contienen proteinas de fusion il-15 / il-15ra fc y dominios de union al antigeno pd-1 y usos de los mismos.
CN112638932A (zh)	2018-04-27	2021-04-09	比奥根Ma公司	人源性抗(聚-ga)二肽重复序列(dpr)抗体
CN113286616A (zh)	2018-05-23	2021-08-20	Adc治疗有限公司	分子佐剂
CA3104684A1 (fr)	2018-07-03	2020-01-09	Bristol-Myers Squibb Company	Procedes de production de proteines recombinees
US12097199B2 (en)	2018-07-09	2024-09-24	Takeda Pharmaceutical Company Limited	Administration of SUMO-activating enzyme inhibitor and anti-CD20 antibodies
CN109273050B (zh) *	2018-08-03	2021-07-13	五邑大学	一种用于解析复杂多聚体蛋白受体的脉冲电子顺磁共振数据的系统及方法与应用
US20210186880A1 (en)	2018-08-03	2021-06-24	Brown University	Oral formulations with increased uptake
CN112771077A (zh)	2018-08-31	2021-05-07	瑞泽恩制药公司	针对cd3/c20双特异性抗体的减轻细胞因子释放综合征的给药策略
AU2019344795A1 (en)	2018-09-17	2021-03-25	The United States Of America, As Represented By The Secretary, Department Of Health And Human Services	Bicistronic chimeric antigen receptors targeting CD19 and CD20 and their uses
EP3861016A2 (fr)	2018-10-03	2021-08-11	Xencor, Inc.	Protéines de fusion fc hétérodimères d'il -12
MA53859A (fr)	2018-10-10	2022-01-19	Boehringer Ingelheim Int	Procédé de transfert de gaz de membrane dans une culture de bioréacteur à haute densité
GB201816554D0 (en)	2018-10-10	2018-11-28	Centauri Therapeutics Ltd	Novel compounds and therapeutic uses thereof
GB201816553D0 (en)	2018-10-10	2018-11-28	Centauri Therapeutics Ltd	Novel compounds and therapeutic uses thereof
CN113329769A (zh)	2018-10-11	2021-08-31	斯克里普斯研究学院	具有反应性精氨酸的抗体化合物及相关的抗体药物缀合物
US20210388101A1 (en)	2018-10-15	2021-12-16	Industry-Academic Cooperation Foundation, Yonsei University	Productivity-enhanced antibody and method for producing same
RU2724469C2 (ru)	2018-10-31	2020-06-23	Закрытое Акционерное Общество "Биокад"	Моноклональное антитело, которое специфически связывается с cd20
US20210403971A1 (en)	2018-11-02	2021-12-30	Kyowa Kirin Co., Ltd.	Method for preparing liquid medium
US20220016277A1 (en)	2018-11-20	2022-01-20	Cornell University	Macrocyclic complexes of radionuclides and their use in radiotherapy of cancer
WO2020117257A1 (fr)	2018-12-06	2020-06-11	Genentech, Inc.	Thérapie combinée de lymphome diffus à grandes cellules b comprenant des immuno-conjugués anti-cd79b, un agent alkylant et un anticorps anti-cd20
EP3891270A1 (fr)	2018-12-07	2021-10-13	Institut National de la Santé et de la Recherche Médicale (INSERM)	Utilisation de cd26 et cd39 en tant que nouveaux marqueurs phénotypiques pour évaluer la maturation de lymphocytes t ffoxp3+ et leurs utilisations à des fins de diagnostic
EP3917500A2 (fr)	2019-01-31	2021-12-08	Elektrofi, Inc.	Formation et morphologie de particules
KR20210126078A (ko)	2019-02-13	2021-10-19	더 브리검 앤드 우먼즈 하스피털, 인크.	항-말초 림프절 어드레신 항체 및 그의 용도
US20220090113A1 (en)	2019-02-18	2022-03-24	Atb Therapeutics	Method of producing a binder-toxin fusion protein in a plant cell or a whole plant
MX2021010313A (es)	2019-02-27	2021-09-23	Genentech Inc	Dosificacion para el tratamiento con anticuerpos anti-tigit y anti-cd20 o anti-cd38.
US11472890B2 (en)	2019-03-01	2022-10-18	Xencor, Inc.	Heterodimeric antibodies that bind ENPP3 and CD3
JP7589168B2 (ja)	2019-04-01	2024-11-25	ジェネンテック，インコーポレイテッド	タンパク質含有製剤を安定化するための組成物および方法
AU2020270920A1 (en)	2019-04-12	2021-11-04	Geltor, Inc.	Recombinant elastin and production thereof
BR112021022815A2 (pt)	2019-05-14	2021-12-28	Genentech Inc	Métodos para tratar linfoma folicular, kits, imunoconjugados e polatuzumabe vedotina
US20220242871A1 (en)	2019-06-10	2022-08-04	Sutro Biopharma, Inc.	5H-PYRROLO[3,2-d]PYRIMIDINE-2,4-DIAMINO COMPOUNDS AND ANTIBODY CONJUGATES THEREOF
EP3983410A1 (fr)	2019-06-17	2022-04-20	Sutro Biopharma, Inc.	Dérivés de 1-(4-(aminométhyl)benzyl)-2-butyl-2h-pyrazolo[3,4-c]quinoléin-4-amine et composés apparentés en tant qu'agonistes du récepteur 7/8 de type toll (tlr), ainsi que des conjugués anticorps-médicament de ceux-ci destinés à être utilisés dans la thérapie et le diagnostic du cancer
CN114514311A (zh)	2019-08-01	2022-05-17	百时美施贵宝公司	改进补料分批细胞培养物中蛋白质产量的方法
US20220339174A1 (en)	2019-08-30	2022-10-27	Vestlandets Innovasjonsselskap As	Method for the treatment of chronic fatigue syndrome using an inhibitory or cytotoxic agent against plasma cells
TW202118512A (zh)	2019-09-12	2021-05-16	美商建南德克公司	治療狼瘡性腎炎之組成物及方法
CN114514035A (zh)	2019-09-13	2022-05-17	伊勒卓菲公司	递送用于治疗疾病的治疗性生物制剂的组合物和方法
PE20221039A1 (es)	2019-10-18	2022-06-17	Genentech Inc	METODOS PARA USAR INMUNOCONJUGADOS ANTI-CD79b PARA TRATAR LINFOMA DIFUSO DE LINFOCITOS B GRANDES
US20230022576A1 (en)	2019-11-19	2023-01-26	Protalix Ltd.	Removal of constructs from transformed cells
JP2023512084A (ja)	2020-01-31	2023-03-23	シージェンインコーポレイテッド	抗ｃｄ３０抗体薬物コンジュゲート及び非ホジキンリンパ腫の治療のためのその使用
US20230065628A1 (en)	2020-02-19	2023-03-02	Elektrofi, Inc.	Droplet Formation and Particle Morphology
US20230095053A1 (en)	2020-03-03	2023-03-30	Sutro Biopharma, Inc.	Antibodies comprising site-specific glutamine tags, methods of their preparation and methods of their use
JP2023522627A (ja)	2020-04-17	2023-05-31	エレクトロフィ，インコーポレイテッド	連続的な液滴形成及び脱水によって粒子を形成する方法
BR112022021441A2 (pt)	2020-04-24	2022-12-13	Genentech Inc	Métodos para tratar linfoma folicular e linfoma difuso de grandes células b e kits
BR112022021625A2 (pt)	2020-04-26	2022-12-06	Biocytogen Pharmaceuticals Beijing Co Ltd	Imunoglobulinas modificadas
EP4148070A4 (fr)	2020-05-03	2024-04-24	Shanghai Miracogen Inc.	Conjugué anticorps-médicament et sa préparation
WO2021231976A1 (fr)	2020-05-14	2021-11-18	Xencor, Inc.	Anticorps hétérodimères qui se lient à l'antigène membranaire spécifique de la prostate (psma) et cd3
GB202007842D0 (en)	2020-05-26	2020-07-08	Quell Therapeutics Ltd	Polypeptide useful in adoptive cell therapy
TW202208619A (zh)	2020-06-24	2022-03-01	美商百歐維拉提夫治療公司	用於純化病毒載體之方法
WO2022031749A1 (fr)	2020-08-03	2022-02-10	Genentech, Inc.	Méthodes diagnostiques et thérapeutiques pour le lymphome
GB202012331D0 (en)	2020-08-07	2020-09-23	Petmedix Ltd	Therapeutic antibodies
KR20230166150A (ko)	2020-08-19	2023-12-06	젠코어 인코포레이티드	항-cd28 조성물
CN112062855B (zh)	2020-08-26	2024-08-30	北京天诺健成医药科技有限公司	一种含有衔接器的药物治疗剂的开发和应用
GB202013477D0 (en)	2020-08-27	2020-10-14	Quell Therapeutics Ltd	Nucleic acid constructs for expressing polypeptides in cells
WO2022043415A1 (fr)	2020-08-27	2022-03-03	INSERM (Institut National de la Santé et de la Recherche Médicale)	Méthodes de détection de la présence d'auto-anticorps spécifiques à un pemphigus dans un échantillon
AU2021339954A1 (en)	2020-09-10	2023-04-13	Genmab A/S	Bispecific antibody against CD3 and CD20 in combination therapy for treating follicular lymphoma
CA3192251A1 (fr)	2020-09-10	2022-03-17	Genmab A/S	Anticorps bispecifique contre cd3 et cd20 en polytherapie pour le traitement un lymphome diffus a grandes cellules b
CN116437956A (zh)	2020-09-10	2023-07-14	健玛保	用于治疗慢性淋巴细胞白血病的针对cd3和cd20的双特异性抗体
BR112023004216A2 (pt)	2020-09-10	2023-04-11	Genmab As	Método para tratar linfoma folicular em um sujeito humano
US20230355753A1 (en)	2020-09-10	2023-11-09	Genmab A/S	Bispecific antibody against cd3 and cd20 in combination therapy for treating diffuse large b-cell lymphoma
KR20230073270A (ko)	2020-09-22	2023-05-25	브리스톨-마이어스 스큅 컴퍼니	치료 단백질의 생산 방법
WO2022074646A1 (fr)	2020-10-05	2022-04-14	Protalix Ltd.	Cellules végétales inactivées de type dicer
WO2022079211A1 (fr)	2020-10-16	2022-04-21	Adc Therapeutics Sa	Glycoconjugués
WO2022103983A2 (fr)	2020-11-11	2022-05-19	Sutro Biopharma, Inc.	Composés de fluorénylméthyloxycarbonyle et de fluorénylméthylaminocarbonyle, conjugués protéines associés et méthodes d'utilisation
WO2022104150A1 (fr)	2020-11-12	2022-05-19	Tg Therapeutics, Inc.	Triple combinaison pour traiter des malignités des lymphocytes b
GB202102396D0 (en)	2021-02-19	2021-04-07	Adc Therapeutics Sa	Molecular adjuvant
WO2022192403A1 (fr)	2021-03-09	2022-09-15	Xencor, Inc.	Anticorps hétérodimériques se liant à cd3 et à cldn6
JP2024509274A (ja)	2021-03-10	2024-02-29	ゼンコアインコーポレイテッド	Ｃｄ３及びｇｐｃ３に結合するヘテロ二量体抗体
EP4454652A2 (fr)	2021-03-15	2024-10-30	F. Hoffmann-La Roche AG	Compositions et méthodes de traitement de la néphropathie lupique
AU2022241765A1 (en)	2021-03-24	2023-11-16	The United States Of America, As Represented By The Secretary, Department Of Health And Human Services	Bicistronic chimeric antigen receptors designed to reduce retroviral recombination and uses thereof
WO2022224980A1 (fr)	2021-04-20	2022-10-27	日本メジフィジックス株式会社	Complexe radioactif d'anticorps anti-cd20, et produit radiopharmaceutique
EP4334354A1 (fr)	2021-05-06	2024-03-13	Dana-Farber Cancer Institute, Inc.	Anticorps anti-alk et leurs procédés d'utilisation
BR112023023622A2 (pt)	2021-05-12	2024-02-06	Genentech Inc	Métodos para tratar linfoma difuso, kits, imunoconjugados, polatuzumabe vedotina e imunoconjugado para uso
US20240270862A1 (en)	2021-06-01	2024-08-15	INSERM (Institut National de la Santé et de la Recherche Médicale)	Use of b cell depleting agents for the treatment of rheumatic heart disease
IL307945A (en)	2021-06-08	2023-12-01	Xyphos Biosciences Inc	NKG2D antibody-ligand region fusion protein
EP4352096A1 (fr)	2021-06-08	2024-04-17	Xyphos Biosciences Inc.	Protéine de fusion de domaine ligand nkg2d-anticorps
CA3220318A1 (fr)	2021-06-17	2022-12-22	Glaxosmithkline Intellectual Property Limited	Anticorps anti-baff destines a etre utilises dans une methode de traitement d'une infection par sars-cov-2 a sequelles de covid prolongees et/ou post-aigues (pasc)
JP2024526122A (ja)	2021-06-17	2024-07-17	ペットメディックス・リミテッド	抗イヌｃｄ２０抗体
JP2024527977A (ja)	2021-07-27	2024-07-26	ノヴァブ，インコーポレイテッド	免疫エフェクター機能を有する操作されたｖｌｒｂ抗体
WO2023015234A1 (fr)	2021-08-05	2023-02-09	Bristol-Myers Squibb Company	Procédés de culture cellulaire pour la production de protéines thérapeutiques
BR112024001970A2 (pt)	2021-08-06	2024-04-30	Petmedix Ltd	Variantes fc de anticorpo
US20240336697A1 (en)	2021-08-07	2024-10-10	Genentech, Inc.	Methods of using anti-cd79b immunoconjugates to treat diffuse large b-cell lymphoma
IL310997A (en)	2021-08-23	2024-04-01	Bioverativ Therapeutics Inc	Factor VIII gene optimization
AR126845A1 (es)	2021-08-23	2023-11-22	Bioverativ Therapeutics Inc	Producción de adn de extremo cerrado con secuencias repetidas de terminal invertida
US20240390869A1 (en)	2021-09-21	2024-11-28	Bristol-Myers Squibb Company	Methods of controlling the level of dissolved oxygen (do) in a solution comprising a recombinant protein in a storage container
WO2023056403A1 (fr)	2021-09-30	2023-04-06	Genentech, Inc.	Méthodes de traitement de cancers hématologiques au moyen d'anticorps anti-tigit, d'anticorps anti-cd38 et d'antagonistes de liaison à l'axe pd-1
AU2022355088A1 (en)	2021-09-30	2024-05-16	Bioverativ Therapeutics Inc.	Nucleic acids encoding factor viii polypeptides with reduced immunogenicity
WO2023097024A1 (fr)	2021-11-24	2023-06-01	Dana-Farber Cancer Institute, Inc.	Anticorps contre ctla-4 et leurs méthodes d'utilisation
US20250051472A1 (en)	2021-12-17	2025-02-13	Dana-Farber Cancer Institute, Inc.	Antibodies and uses thereof
CA3241407A1 (fr)	2021-12-17	2023-06-22	Dana-Farber Cancer Institute, Inc.	Plateforme pour decouverte d'anticorps
JP2025503177A (ja)	2022-01-28	2025-01-30	ジェンマブエー／エス	びまん性大細胞型ｂ細胞リンパ腫を治療するための併用療法におけるｃｄ３及びｃｄ２０に対する二重特異性抗体
WO2023150552A1 (fr)	2022-02-04	2023-08-10	Dana-Farber Cancer Institute, Inc.	Compositions et méthodes de traitement de troubles neurologiques
EP4476256A1 (fr)	2022-02-09	2024-12-18	Petmedix Ltd.	Anticorps thérapeutiques
WO2023164487A1 (fr)	2022-02-22	2023-08-31	Brown University	Compositions et procédés pour obtenir une absorption systémique de particules suite à une administration par voie orale ou muqueuse
CN118974091A (zh)	2022-04-11	2024-11-15	阿斯利康(瑞典)有限公司	T细胞结合蛋白
AU2023260936A1 (en)	2022-04-29	2024-12-05	Elektrofi, Inc.	Injectable suspensions
US11807689B1 (en)	2022-06-01	2023-11-07	Tg Therapeutics, Inc.	Anti-CD20 antibody compositions
US11965032B1 (en)	2022-06-01	2024-04-23	Tg Therapeutics, Inc.	Anti-CD20 antibody compositions
US11884740B1 (en)	2022-06-01	2024-01-30	Tg Therapeutics, Inc.	Anti-CD20 antibody compositions
US11814439B1 (en)	2022-06-01	2023-11-14	Tg Therapeutics, Inc.	Anti-CD20 antibody compositions
WO2024006272A1 (fr)	2022-06-27	2024-01-04	Sutro Biopharma, Inc.	CHARGES UTILES DE LIEUR β-GLUCURONIDE, LEURS CONJUGUÉS PROTÉIQUES ET MÉTHODES ASSOCIÉES
WO2024015229A1 (fr)	2022-07-15	2024-01-18	Sutro Biopharma, Inc.	Charges utiles-lieurs clivables par une protéase/enzyme et conjugués protéiques
AU2023324667A1 (en)	2022-08-15	2025-02-13	Dana-Farber Cancer Institute, Inc.	Antibodies against cldn4 and methods of use thereof
WO2024039672A2 (fr)	2022-08-15	2024-02-22	Dana-Farber Cancer Institute, Inc.	Anticorps anti-mlsn et leurs méthodes d'utilisation
TW202434286A (zh)	2022-11-08	2024-09-01	美商建南德克公司	治療兒童期發病的特發性腎病症候群之組成物及方法
WO2024153636A1 (fr)	2023-01-17	2024-07-25	Institut National de la Santé et de la Recherche Médicale	Vasorine en tant que biomarqueur et biocible en néphrologie
WO2024182516A1 (fr)	2023-02-28	2024-09-06	Juno Therapeutics, Inc.	Thérapie cellulaire pour le traitement de maladies auto-immunes systémiques
WO2024254455A1 (fr)	2023-06-08	2024-12-12	Genentech, Inc.	Signatures de macrophages pour méthodes diagnostiques et thérapeutiques pour un lymphome
WO2025021782A1 (fr)	2023-07-24	2025-01-30	Institut National de la Santé et de la Recherche Médicale	Procédés pour déterminer si un sujet souffrant de néphrite lupique (ln) est sensible à une thérapie par induction
WO2025029832A2 (fr)	2023-07-31	2025-02-06	Sutro Biopharma, Inc.	Composés agonistes de sting et conjugués

Family Cites Families (29)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US147885A (en) *		1874-02-24		Improvement in the manufacture of halters and bridles
US21781A (en) *		1858-10-12		Improved method o f lighting street-lamps by electricity
US163708A (en) *		1875-05-25		Improvement in harvester-rakes
US95963A (en) *		1869-10-19		Improvement in fence
US26804A (en) *		1860-01-10		Bridle-bit
US186205A (en) *		1877-01-16		Improvement in buffing-rolls for thesoles of boots andshoes
US206903A (en) *		1878-08-13		Improvement in cultivators
US9444A (en) *		1852-12-07		Hot-air furnace
US213784A (en) *		1879-04-01		Improvement in inlaying metallic scroll-ornaments in hard rubber and allied gums
US197255A (en) *		1877-11-20		Improvement in receivers and stench-traps for street-sewers
US4816567A (en) *	1983-04-08	1989-03-28	Genentech, Inc.	Recombinant immunoglobin preparations
EP0173494A3 (fr) *	1984-08-27	1987-11-25	The Board Of Trustees Of The Leland Stanford Junior University	Récepteurs chimériques par liaison et expression de l'ADN
USRE38008E1 (en) *	1986-10-09	2003-02-25	Neorx Corporation	Methods for improved targeting of antibody, antibody fragments, hormones and other targeting agents, and conjugates thereof
US6893625B1 (en) *	1986-10-27	2005-05-17	Royalty Pharma Finance Trust	Chimeric antibody with specificity to human B cell surface antigen
IL85035A0 (en) *	1987-01-08	1988-06-30	Int Genetic Eng	Polynucleotide molecule,a chimeric antibody with specificity for human b cell surface antigen,a process for the preparation and methods utilizing the same
US4975278A (en) *	1988-02-26	1990-12-04	Bristol-Myers Company	Antibody-enzyme conjugates in combination with prodrugs for the delivery of cytotoxic agents to tumor cells
US5204244A (en) *	1987-10-27	1993-04-20	Oncogen	Production of chimeric antibodies by homologous recombination
US5439665A (en) *	1988-07-29	1995-08-08	Immunomedics	Detection and treatment of infectious and inflammatory lesions
IL162181A (en) *	1988-12-28	2006-04-10	Pdl Biopharma Inc	A method of producing humanized immunoglubulin, and polynucleotides encoding the same
JPH06501705A (ja) *	1990-11-05	1994-02-24	ブリストル−マイアーズ　スクイブ　カンパニー	抗−腫瘍抗体及び生物学的活性剤の組合せによる相乗治療
MX9204374A (es) *	1991-07-25	1993-03-01	Idec Pharma Corp	Anticuerpo recombinante y metodo para su produccion.
US5686072A (en) *	1992-06-17	1997-11-11	Board Of Regents, The University Of Texas	Epitope-specific monoclonal antibodies and immunotoxins and uses thereof
PT752248E (pt) *	1992-11-13	2001-01-31	Idec Pharma Corp	Aplicacao terapeutica de anticorpos quimericos e marcados radioactivamente contra antigenios de diferenciacao restrita de linfocitos b humanos para o tratamento do linfoma de celulas b
US5736137A (en) *	1992-11-13	1998-04-07	Idec Pharmaceuticals Corporation	Therapeutic application of chimeric and radiolabeled antibodies to human B lymphocyte restricted differentiation antigen for treatment of B cell lymphoma
US5648267A (en) *	1992-11-13	1997-07-15	Idec Pharmaceuticals Corporation	Impaired dominant selectable marker sequence and intronic insertion strategies for enhancement of expression of gene product and expression vector systems comprising same
US5595721A (en) *	1993-09-16	1997-01-21	Coulter Pharmaceutical, Inc.	Radioimmunotherapy of lymphoma using anti-CD20
US5678180A (en) *	1995-06-07	1997-10-14	Hughes Electronics	Communication system and method providing dispatch and cellular interconnect communications
US6183744B1 (en) *	1997-03-24	2001-02-06	Immunomedics, Inc.	Immunotherapy of B-cell malignancies using anti-CD22 antibodies
US6306393B1 (en) *	1997-03-24	2001-10-23	Immunomedics, Inc.	Immunotherapy of B-cell malignancies using anti-CD22 antibodies

1993
- 1993-11-03 US US08/149,099 patent/US5736137A/en not_active Expired - Lifetime
- 1993-11-12 ES ES08013898T patent/ES2326144T3/es not_active Expired - Lifetime
- 1993-11-12 AT AT99123967T patent/ATE421335T1/de active
- 1993-11-12 AT AT08013898T patent/ATE431158T1/de active
- 1993-11-12 CA CA002626445A patent/CA2626445A1/fr not_active Withdrawn
- 1993-11-12 PT PT08013898T patent/PT2000149E/pt unknown
- 1993-11-12 CN CN2004100488083A patent/CN1607006B/zh not_active Expired - Lifetime
- 1993-11-12 DE DE69334285T patent/DE69334285D1/de not_active Expired - Lifetime
- 1993-11-12 CN CN200610090080XA patent/CN101007850B/zh not_active Expired - Lifetime
- 1993-11-12 ZA ZA938466A patent/ZA938466B/xx unknown
- 1993-11-12 SG SG1996002951A patent/SG45294A1/en unknown
- 1993-11-12 KR KR1019950701928A patent/KR100365632B1/ko not_active IP Right Cessation
- 1993-11-12 CN CN2006100900848A patent/CN101007851B/zh not_active Expired - Lifetime
- 1993-11-12 DK DK08013898T patent/DK2000149T3/da active
- 1993-11-12 UA UA95062664A patent/UA27946C2/uk unknown
- 1993-11-12 HU HU9501410A patent/HU219264B/hu active Protection Beyond IP Right Term
- 1993-11-12 CN CN2006100900829A patent/CN1912111B/zh not_active Expired - Lifetime
- 1993-11-12 PT PT99123967T patent/PT1005870E/pt unknown
- 1993-11-12 DK DK99123967T patent/DK1005870T3/da active
- 1993-11-12 CN CNB931214246A patent/CN1270774C/zh not_active Expired - Lifetime
- 1993-11-12 MY MYPI93002374A patent/MY111196A/en unknown
- 1993-11-12 PL PL93320526A patent/PL175557B1/pl unknown
- 1993-11-12 ES ES99123967T patent/ES2321567T3/es not_active Expired - Lifetime
- 1993-11-12 EP EP08013898A patent/EP2000149B1/fr not_active Expired - Lifetime
- 1993-11-12 DE DE69334259T patent/DE69334259D1/de not_active Expired - Lifetime
- 1993-11-12 IL IL10759193A patent/IL107591A/xx not_active IP Right Cessation
- 1993-11-12 DE DE122009000070C patent/DE122009000070I1/de active Pending
- 1993-12-14 TW TW082110578A patent/TW376320B/zh not_active IP Right Cessation
1997
- 1997-05-13 BR BR1100622-6A patent/BR1100622A/pt active IP Right Grant
2002
- 2002-03-14 US US10/096,964 patent/US20030082172A1/en not_active Abandoned
2004
- 2004-07-15 FR FR04C0018C patent/FR04C0018I2/fr active Active
2006
- 2006-07-07 GE GEAP20069498A patent/GEP20074162B/en unknown
2008
- 2008-01-11 HK HK08100410.4A patent/HK1109634A1/xx not_active IP Right Cessation
- 2008-01-11 HK HK08100409.7A patent/HK1109633A1/xx not_active IP Right Cessation
2009
- 2009-05-13 HK HK09104369.6A patent/HK1125574A1/xx not_active IP Right Cessation
- 2009-11-10 NL NL300424C patent/NL300424I1/nl unknown
- 2009-11-11 LU LU91620C patent/LU91620I2/fr unknown
2010
- 2010-01-06 GE GEAP201011620A patent/GEP20105119B/en unknown
- 2010-01-06 GE GEAP200911620A patent/GEPI20105119B/en unknown

Also Published As

Publication number	Publication date
TW376320B (en)	1999-12-11
CN1270774C (zh)	2006-08-23
CN1912111B (zh)	2010-05-26
ES2326144T3 (es)	2009-10-01
DE69334285D1 (de)	2009-06-25
BR1100622A (pt)	2000-04-18
ES2321567T3 (es)	2009-06-08
DE69334259D1 (de)	2009-03-12
MY111196A (en)	1999-09-30
US20030082172A1 (en)	2003-05-01
DK2000149T3 (da)	2009-08-03
ZA938466B (en)	1994-06-20
CN101007850A (zh)	2007-08-01
LU91620I2 (fr)	2010-01-11
HUT72914A (en)	1996-06-28
CN101007851A (zh)	2007-08-01
PT2000149E (pt)	2009-07-14
HK1109633A1 (en)	2008-06-13
GEP20074162B (en)	2007-07-10
EP2000149A1 (fr)	2008-12-10
US5736137A (en)	1998-04-07
CN101007850B (zh)	2012-05-30
KR100365632B1 (ko)	2003-08-02
PT1005870E (pt)	2009-04-28
EP2000149B1 (fr)	2009-05-13
NL300424I1 (nl)	2010-01-04
DK1005870T3 (da)	2009-05-18
CA2626445A1 (fr)	1994-05-26
PL175557B1 (pl)	1999-01-29
HK1109634A1 (en)	2008-06-13
UA27946C2 (uk)	2000-10-16
GEPI20105119B (en)	2010-11-25
ATE431158T1 (de)	2009-05-15
HK1125574A1 (en)	2009-08-14
ATE421335T1 (de)	2009-02-15
DE122009000070I1 (de)	2010-02-11
CN101007851B (zh)	2012-09-12
FR04C0018I2 (fr)	2009-11-20
SG45294A1 (en)	1998-01-16
CN1607006A (zh)	2005-04-20
GEP20105119B (en)	2010-11-25
CN1094965A (zh)	1994-11-16
CN1912111A (zh)	2007-02-14
HU219264B (en)	2001-03-28
HU9501410D0 (en)	1995-06-28
CN1607006B (zh)	2012-09-19
FR04C0018I1 (fr)	2008-09-26
IL107591A0 (en)	1994-02-27

Publication	Publication Date	Title
IL107591A (en)	2000-02-17	Anti B cell antibodies their preparation and pharmaceutical compositions comprising them
EP1005870A3 (fr)	2002-10-23	Application thérapeutique d'anticorps chimériques et radio-marqués contre l'antigène à differentiation restreinte des lymphocytes B humains pour le traitement du lymphome des cellules B

Legal Events

Date	Code	Title
2000-06-29	FF	Patent granted
2004-02-08	KB	Patent renewed
2008-01-06	KB	Patent renewed
2011-11-30	KB	Patent renewed
2014-06-30	EXP	Patent expired